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My research focus was to investigate alligator blood using mass spectrometry-based 
proteomics methods to understand their innate immune systems. The first goal was to sequence 
peptides and proteins from the blood serum and leukocytes using tandem mass spectrometry and 
de novo sequencing. The second goal was to determine the function of these biological 
molecules and their relationship to the immune system.  
One- and two-dimensional gel electrophoresis was used to separate proteins from 
alligator leukocytes, which were enzymatically digested. The peptides were measured using 
reversed phase nano-high performance liquid chromatography coupled with tandem mass 
spectrometry (nano-HPLC-MS/MS) followed with de novo sequencing. The results, as described 
in Chapter 3 show that alligator leukocytes contain proteins that are similar to proteins found in 
other vertebrates such as mammals and reptiles that are related to immune responses. Isolation of 
small molecule interferences and peptides exhibiting antimicrobial activity from alligator 
leukocyte extracts are described in Chapters 4 and 5. Reversed-phase HPLC was used to separate 
the leukocyte mixture and antimicrobial activity tests were used to determine the active fractions. 
Interferants, EDTA and spermine were present and showed activity in early fractions. Two major 
peptides measured at 4.7 and 4.9 kDa in an active fraction were further separated on the basis of 
their charge, size and shape using ion mobility-mass spectrometry (IM-MS). Due to the limited 
fragmentation of the peptides using IM-MS, the peptides were isolated and fragmented using 
MALDI TOF/TOF MS for de novo sequencing.  
Lectins are a class of carbohydrate selective proteins that are part of the complement 
immune system. Chapter 6 presents results for a lectin isolated from alligators that have mannan 
and mannose binding activity. In this study, the monomeric lectin was isolated and enzymatically 
digested using five different proteases to create small and large peptides which were analyzed by 
xvii 
 
LC-MS/MS. The peptides were determined via de novo sequencing and overlapped to generate 
the lectin sequence. Lectins may have varying degrees of glycosylation, therefore 
deglycosylation procedures suitable for mass spectrometry analysis are described in Chapter 7. 









CHAPTER 1. INTRODUCTION 
 
Alligators exhibit strong immune responses when exposed to microorganisms, and are 
highly resistant to microbial infections.1-3 Therefore, characterization of biological components 
that make up the immune system of alligators is of interest because these compounds may have 
therapeutic applications. Antibiotic resistance has become a global public health issue and is 
increasing at a rate that exceeds the pace of the development of new drugs. Hence, isolation of 
antimicrobial peptides from alligators may lead to a new class of antibiotics. 
Another class of molecules that are part of the immune system is the set of proteins 
known as lectins, which show promise for their application in cancer therapy, pharmacology and 
immunology.5 The study of lectins isolated from Alligator mississippiensis, can provide insight 
on its structure-function relationship within the crocodile’s immune system.  
The goal of this research was to use mass spectrometry-based proteomics to isolate and 
characterize biological molecules in alligator blood and identify specific components that may 
have medicinal use. 
1.1 Biochemistry of the Immune System 
The vertebrate immune system is composed of a network of circulating cells and 
molecules7 that recognize and respond to the invasion of foreign pathogens such as viruses, 
bacteria, fungi and protists.8 These molecules include antimicrobial molecules such as lysozymes 
and defensins, molecules involved in specific recognition of foreign antigens such as 
immunoglobulins and T-cell receptors, molecules that carry intracellular signals such as 
cytokines, and molecules that receive and transduce these signals such as cytokine receptors.8 
Vertebrates have both innate and adaptive immune systems that work together.7 The innate 
immune system responds rapidly and is the first line of defense against pathogens and does not 
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require previous exposure to exhibit a full immunological response.7 In contrast to the innate 
immune system, the adaptive immune system requires previous exposure to an antigen to exhibit 
a full immunological response and can take several days to weeks to become completely active.7  
Most studies on vertebrate immune systems have been performed on mammals8 and the 
evolutionary development of the immune systems of major group of vertebrates, including 
mammals, birds, amphibians and fish is well known compared to other groups of organisms.8 In 
contrast, little is known about the reptilian immune systems.8 A better understanding of reptilian 
immunology will provide important information on the evolution of both innate and adaptive 
immune mechanisms. Crocodilians are of interest because they are the only living reptilian 
archosaurs, which include the dinosaurs, pterosaurs, and crocodilians.9  
Crocodilians are vertebrates with a complex immune system. The components that make 
up the reptilian immune system are antimicrobial peptides, macrophages, heterophils, 
neutrophils, basophils, eosinophils, phagocytic B cells, and proteins of the complement system. 
Like other vertebrates, crocodilians also have an innate and adaptive immune system.7, 10 
Crocodilians thrive in microbe containing environments but exhibit a strong resistance to 
infections.  
Alligator serum has been shown to have antibacterial,3 antiviral,2 and antiamoebacidal 
properties.11 Antibacterial activity has also been observed in crocodile serum, particularly 
Crocodylus siamensis.12, 13 In addition, the leukocytes of Alligator mississippiensis have also 
shown to produce a broad antimicrobial spectrum.1 The alligator complement system, which is 
part of the innate immune system, has also been shown to be effective against gram-positive 
bacteria.3, 14 When alligator serum was compared to human serum, the alligator serum was 
effective against different strains of Gram-positive bacteria, unlike human serum which had no 
antibacterial activity. It was proposed that the complement is also responsible for antiviral 
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activity from the alligator serum. Human T-cells were infected with human immunodeficiency 
virus type 1 (HIV-1) and when incubated with alligator serum potent antiviral activity was 
observed.2 These studies suggest that crocodilians have a strong innate immune system. 
1.1.1 Innate Immune System 
The innate immune system comprises different molecules and cells including lysozymes, 
proteins of the complement system, non-specific leukocytes, and antimicrobial peptides.7 
Lysozymes are enzymes that cause bacteria cells to be lysed by the hydrolysis of their cell wall.15 
Lysozymes have been isolated from several reptilian organisms such as, lizards,16 turtles,16 
crocodiles,17 and alligators6. The complement system consists of various proteins found in 
plasma that kill bacteria via lysis or opsonization.7 Lysis entails the complement proteins 
rupturing the bacterial membrane therefore killing the invading bacteria.18 Opsonization is the 
process by which opsonin proteins found in blood serum, bind to the bacterial membrane 
allowing the bacteria to be recognized by macrophages. The macrophages then engulf the 
bacteria through phagocytosis.7   
There are three different pathways to the complement immune system: classical, 
alternative, and lectin.19 The classical pathway is activated by the immunoglobulins, 
immunoglobulin G (IgG) and immunoglobulin M (IgM) to activate an immune response.7, 19 The 
alternative pathway does not require antibodies but is activated by molecules such as viruses or 
lipopolysaccharide (LPS) that are found on the surface of bacteria.18 Finally, the lectin pathway 
is activated by mannose sugars of proteins that are on the surface of bacteria.19 The complement 
immune system has been characterized in the American alligator14 and is believed to be 
responsible for antiviral activity exhibited by alligator serum.2 
There are non-specific leukocytes in reptiles including eosinophils, herterophils, 
basophils, monocytes, and macrophages.7 Limited information is known about the function of 
4 
 
eosinophils in reptiles; however, in mammals they play a key role in the defense against parasitic 
infections.19 Heterophils are involved in the inflammatory response in reptiles and are also 
responsible for suppressing microbial invasion.20 Basophils contain immunoglobulins on their 
surface and when triggered by an antigen releases histamine.21 Monocytes and macrophages are 
phagocytic cells that are responsible for processing and releasing antigens as well as releasing 
cytokines.19 Cytokines are regulatory proteins that are released by the cells of the immune 
system to generate an immune response.22  
An important component of the innate immune system is antimicrobial peptides and 
proteins. Antimicrobial peptides are found in the host defense system and exhibit antimicrobial 
activity.23 Antimicrobial molecules are typically amphipathic and cationic small peptides less 
than10 kDa in mass.24 However, they can also be anionic peptides25 or proteins.26 Antimicrobial 
peptides can be linear and α-helical or cysteine containing and β-sheet. The linear peptides 
typically consist of 12–25 residues and no cysteines.24 The β-sheet peptides have several 
antiparallel β-strands and are stabilized with up to six disulfide bonds.24 There are also 
antimicrobial peptides that are rich in specific residues, such as tryptophan,27 proline, and/or 
arginine28, 29 and histidine.30        
There are two major antimicrobial peptide families found in vertebrates:  defensins and 
cathelicidins. Defensins are antimicrobial peptides that are rich in arginine residues and have a 
characteristic β-sheet fold and six disulfide linked cysteines.23 They are cationic peptides that 
bind to microbes via electrostatic interactions.31 Defensins have been found in mammals and 
birds32 and recently the first reptilian defensin was discovered in the European pond turtle Emys 
orbicularis.33 Defensins are 38-42 residues and found in cells and tissues involved in the host 
defense system. In many animals the highest concentration of defensins are found in the 
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granules, where the leukocytes are stored.23 Defensins exhibit antibacterial, antifungal, and 
antiviral activity.23  
Another family of antimicrobial peptides is the cathelicidins. Cathelicidins are linear 
molecules that range in size from 12 to 80 amino acids and, unlike the β-defensins, they lack 
disulfide bridges.34 Cathelicidins have antifungal35 and antibacterial activity.36 They have been 
isolated from fish,37 birds,38 mammals,39 and reptiles.40 Cathelicidins are produced in the myeloid 
cells in the bone marrow and stored in the neutrophil granules.41 Cathelicidins have also been 
found in monocytes, epithelial cells of the skin, respiratory tract, urogenital tract, as well as T 
and B lymphocytes.41 
The membranes of microbes and multicellular animals differ in that microbes, 
particularly bacteria, have an outer membrane surface that is composed of lipids with negatively 
charged phospholipid head groups. The outer membranes of plants and animals are composed of 
lipids that do not have a net negative charge (Figure 1-1); the negatively charged head groups are 
positioned towards the cytoplasm.42, 43 
The primary model that explains the mechanism of antimicrobial peptides is the Shai-
Matsuzaki-Huang model.43, 44 The Shai-Matsuzaki-Huang Model postulates that the peptide 
interacts with the pathogen membrane, displacing the lipids and disrupting the membrane 
structure. In some cases the peptide may also penetrate the cell.44 The membrane of multicellular 
animal cells contains cholesterol, which reduces the activity of the antimicrobial peptide via 
peptide interaction with the cholesterol or stabilization of the lipid bilayer. In addition to this 
proposed mechanism, studies suggest that there are other mechanisms involved. These 
mechanisms include 1) depolarization of the bacterial membrane leading to death,45 2) creation 
of holes in the cell causing cellular leakage,46 3) activation of processes that cause cell death (e.g. 






























































































The broad antimicrobial spectrum of the antimicrobial peptides allows them to be used 
for diverse applications. However, a major drawback of antimicrobial peptides for clinical use is 
the level of toxicity. The level at which the antimicrobial peptides are effective in vivo are 
usually toxic.52 Other factors are stability and immunogenicity.49  
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Another group of molecules that play an important role in vertebrate innate immune 
systems is lectins. Lectins have been studied for more than 100 years in plants and have recently 
been recognized for their importance in animals.54 Lectins are proteins that can recognize 
carbohydrates that are endogenous to the animal or those on microbes.55 They have been 
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classified based on their carbohydrate ligands, biological processes, subcellular location, and 
dependence on divalent cations.55 They have a wide range of structures, but carbohydrate-
binding activity is limited to a particular region of the protein known as the carbohydrate-
recognition domain (CRD).56   
Animal lectins are grouped into two structural families: C-type and S-type.56 C-type 
lectins are found in serum, extracellular matrix, and plasma membranes. They require calcium 
for binding and bind to a variety of sugars. S-type lectins are found intracellularly and require 
sulfydryl for binding to β-galactosides.57  
Animal lectins possess a wide variety of functions such as cellular growth regulation, 
mediation of endocytosis, intracellular routing of glycoconjugates, and urate transport.58 
However, the major function of lectins is to behave as recognition molecules within the immune 
system.58 These roles within the immune system include: direct defense, cell recognition and 
trafficking, immune regulation, and prevention of autoimmunity.58 Different applications of 
lectins have been demonstrated such as immobilization onto columns for affinity separation of 
glycoproteins, glycopeptides and oligosaccharides,59 selective agglutination,60 and blood 
typing.61 Lectins show promise for their application in agriculture, cancer therapy, 
pharmacology, and immunology.5  
1.1.2 Adaptive Immune System 
The adaptive immune system becomes activated following the innate immune response. 
There are two adaptive immunity responses:  cell-mediated and humoral adaptive immunity.7 
Cell-mediated immunity involves T-cells that are responsible for regulating antibody production. 
T-cells can differentiate into two types of cells: cytotoxic T-cell (TC) or T helper cell (TH). TC 
can rapidly kill bacterial or viral infected cells through apotosis. TC regulates other immune 
cells. TH helps control other immune cells. T-cells also release cytokines that affect the humoral 
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response (the immune responses mediated by antibodies).7 Humoral adaptive immunity relies on  
B-cells that recognize antigens even before being processed.19  
1.1.3 Study of the Immune System 
To study the immune system of vertebrates, serological assays are typically used, in 
which in vitro reactions between antigen and serum antibodies are studied.62 There are many 
different types of serological assays including agglutination, precipitation, immunoassays, 
immunofluorescence, fluorescence-activated cell sorting analysis, and lymphocyte function.62 
These assays help elucidate the immune system’s functional and regulatory properties through 
lymphocyte function measurements and the responses of B- and T-cells as well as antibodies.  
Another approach to studying the immune system is hematology, which is the study of 
blood, including white blood cells, red blood cells, hemoglobin, and platelets.62 Hematological 
tests allow for observation of live blood (whole blood that is unaltered and unstained) with 
microscopy. Using this test, microbial activity in the blood and its potential effects can be 
measured. In addition, the white blood cells can be quantified, which can provide insight on how 
the immune system is functioning. There is also the standard blood microscopy technique in 
which the blood is stained and fixed; however, staining kills the blood cells.  
Another technique for studying the immune system is genomics and proteomics, which is 
discussed in Section 1.2. Genomics and proteomics provide a more comprehensive view of the 
immune system and its function as compared to serological assays and hematology tests. 
1.2 Chemical Analysis Methods for Proteomics 
Proteomics is the approach used to understand complex biological systems by analyzing 
protein expression, function, modifications, and interactions.63 Proteomics is related to genomics, 
which is the study of the genetic make-up of an organism.64 An important step towards 
understanding an organism’s biology is to determine its genome sequence. However, the genome 
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sequence is not enough to provide information on complex cellular processes; the complement of 
proteins associated with a particular genome is essential to this understanding.65  
Proteomics is complimentary to genomics and provides an additional component to the 
understanding of biological systems. However, there are significant challenges in proteomics 
such as limited sample quantity, sample degradation, broad dynamic range (>106 fold for protein 
abundance), post-translational modifications, and disease changes.66 Protein concentrations 
typically exceed the dynamic range of a single analytical instrument or method necessitating the 
use of one or more dimensions of separation.63  
Proteomics can be divided into three major branches: structural proteomics,67 expression 
proteomics,68 and functional proteomics.68 Structural proteomics involves determining the 
structures of proteins, such as its three-dimensional shape (secondary and tertiary structure) and 
its amino acid sequence (primary structure).67 A commonly used approach for protein 
sequencing is Edman degradation. Edman degradation was developed by Pehr Edman in 1950 
and is one of the oldest and most developed techniques for protein sequencing.69 However, 
Edman sequencing chemistry has largely been replaced by mass spectrometry for protein 
sequencing and identification.70, 71 Protein secondary and tertiary structures can be characterized 
by X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy.67  
Expression proteomics involves the quantitative and qualitative analysis of proteins under 
different conditions.68 This approach allows disease-specific proteins to be identified by 
comparing the entire proteome between two samples. Proteins that are over-expressed or under-
expressed can be identified and characterized. The techniques commonly used for expression 
proteomics are two-dimensional gel electrophoresis,72 multi-dimensional chromatography with 
mass spectrometry,73 and micro-array techniques.74 Two-dimensional electrophoresis suffers 
from  limitations such as the large dynamic range of protein expression in biological systems and 
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difficulty in analyzing proteins that are post-translationally modified.68 Limitations of microarray 
technology include the sensitivity of the arrays for detection of low abundance genes75 as well as 
its inability to measure post-translational modifications.76 Unlike 2-D electrophoresis and micro-
array techniques, multi-dimensional chromatography with mass spectrometry can measure post-
translational modifications in expression proteomics.77 
Functional proteomics is an approach to analyze and understand the properties of 
macromolecular networks involved in cells.68 Proteins and their specific roles in metabolic 
activities can be identified.  
1.2.1 Sample Purification 
Blood plasma and serum are commonly used biological fluids for proteomic analysis 
because many cells release a portion of their content into the plasma when damaged or upon cell 
death. There are approximately 10,000 proteins present in human serum78 and many proteins of 
interest are present in low abundance. Plasma comprises ~97% high abundance proteins 
including albumin (57–71%) and immunoglobulins (8–26%).79 Hence plasma samples are 
difficult to analyze directly and purification is required. In addition, proteomic samples usually 
contain a large amount of contaminants such as lipids, nucleic acids, and surfactants.80 The 
dynamic range of expressed proteins is greater than six orders of magnitude81 and protein 
mixtures can be quite complex and contain proteins with different solubility, hydrophobicity and 
hydrophilicity, pI, and molecular masses.82 Therefore, sample purification is necessary before 
mass spectrometry analysis.  
Separation methods such as affinity-based techniques, chromatography and 
centrifugation have been employed.83 It is important that the proteins of interest are well resolved 
with limited sample purification steps to avoid sample loss. Affinity-based techniques have been 
established for removal of albumin and IgG using immobilized antibodies that are selective 
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against albumin84 and protein A or protein G that selectively capture IgG on the columns.85 The 
removal of salts and other contaminants from protein samples has been accomplished using 
precipitation with centrifugation.80 Commonly used precipitation methods include acetone, 
trichloroacetic acid (TCA), ammonium sulfate, and chloroform/methanol precipitation.  
1.2.2 Digestion 
Protein digestion can be performed using three common approaches: in-gel,86, 87 in-
solution,88 or solid phase.89, 90 In an in-gel digestion, the proteins are separated on a 1- or 2-D gel 
and the gel bands are excised for chemical or proteolytic digestion.87 A major advantage of in-gel 
digestion is that it removes detergents and salts that can be interfants in the mass spectrometer.87 
However, a limitation to this method is the loss of peptides during in-gel digestion through 
binding to the polyacrylamide.87 Another approach that has been developed is in-solution 
digestion which entails digesting proteins directly in buffers or solvents such as ammonium 
bicarbonate or acetonitrile.91 This approach is advantageous in that low abundance molecules 
that may otherwise be lost in the gel can be detected. A drawback for this method includes longer 
incubation times due to lower enzymatic concentrations.92 Solid phase is another digestion 
approach which includes immobilization of an endoprotease on a solid support; examples include 
monolithic columns for trypsin digestion93 and microfluidic devises with integrated trypsin 
digestion.90 Solid phase digestion offers advantages of increased digestion rates, reduced 
interferences from trypsin autolysis products, low sample consumption, and fast response.94, 95 A 
limitation to this method is the use of organic solvents which improve digestion efficiency but 
can damage the immobilized enzyme.96  
Digestion efficiency can be improved by cysteine reduction before digestion. The 
disulfide bonds are reduced with a reagent such as dithiothreitol (DTT) and an alkylation reaction 
is performed with iodoacetamide to prevent new disulfide bridges from forming.97  
13 
 
Many of the endoproteases and chemicals cleave proteins at specific amino acids 
generating peptide fragments of varying lengths. Peptide fragments between 6–20 amino acids 
are best for MS analysis and protein database searching.98 Endoproteases and chemicals used for 
protein analysis are indicated in Table 1-2. The most commonly used endoprotease for proteomic 
analysis is trypsin. Trypsin cleaves at lysine and arginine residues, unless followed by a proline 
residue in the C-terminus direction.99 Trypsin has good activity in both in-gel and in-solution 
digests. 
 
Table 1-2. Chemicals and proteases used for enzymatic and chemical cleavage. Cleavage with 
the endoproteases only occurs if the residue after the cleavage site is not proline, except for Asp-
N.100  
 
Endoproteases Cleavage Specificity 
Trypsin K, R 




Chymotrypsin W, Y, F, L, M 
Chemical Agents Cleavage Specificity 
70% Formic acid D 
Cyanogen bromide M 
2-nitro-5-thiocyanobenzoate, pH 9101 C 
Hydroxylamine, pH 9102 N, G 
Iodobenzoic acid W 
 
Many proteins contain a significant number of lysine and arginine residues that are 
spaced sufficiently in the sequence so that trypsin produces fragments that are a suitable length 
for MS analysis. Another complementary enzyme used is Glu-C which cleaves at the carboxyl 
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side of glutamate residues.103, 104 In the presence of selected buffers such as sodium phosphate, it 
can cleave at both the glutamate and aspartate residues. Other proteases listed in Table 2 with 
cleavage specificities are useful for producing peptides of varying lengths depending on how 
many cleavages occur. This is useful for obtaining additional sequence information, especially if 
the protein is unknown.  
There are also non-specific endoproteases such as pepsin as well as endoproteases with 
broad specificities such as chymotrypsin that are useful for producing multiple overlapping 
peptides that can increase sequence coverage.98 Proteins can also be cleaved with cyanogen 
bromide, formic acid, and hydroxylamine. Cyanogen bromide is the most commonly used for 
protein cleavage; it cleaves specifically at methionine residues.105  
1.2.3 Separations 
Two separation methods used in proteomics are gel electrophoresis and liquid 
chromatography (LC). Gel electrophoresis is a sensitive method for separating and identifying 
proteins in a gel matrix such as agarose or polyacrylamide.80 Agarose is typically used to 
separate larger macromolecules such as nucleic acids and polyacrylamide is typically used to 
separate proteins. Polyacrylamide gel electrophoresis can be used to determine the size, 
isoelectric point and purity of proteins.80 The gel pores are made by crosslinking of the 
polyacrylamide with bis-acrylamide to form a network of pores that allows the molecules to 
move through the gel matrix like a sieve. The gel pore size is determined by the acrylamide 
monomer concentration.106  
Gel electrophoresis separates molecules based on the differences in migration velocity of 
ions in the gel under the influence of an electric field. The migration velocity is the product of 
the electrophoretic mobility and the applied electric field. The electrophoretic mobility is 
proportional to the ion charge and inversely proportional to the frictional forces. The frictional 
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forces depend on the analyte size and the viscosity of the solvent. Smaller analytes have a greater 
mobility and migrate farther down the medium in a given time.  Polyacrylamide gel 
electrophoresis (PAGE) is used to separate proteins and peptides based on their size. Sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) is the most commonly used 
gel based technique for separating proteins. SDS is used to denature the proteins and gives the 
protein an overall net negative charge.107    
Two-dimensional gel electrophoresis (2D-GE) is used to separate proteins based on their 
charge and mass.107, 108 The first dimension separates proteins based on their net charge using 
isoelectric focusing.108 Protein separation is performed in a pH gradient; the proteins migrate to 
their isoelectric point (pI), which is the pH where the protein has a net charge of zero. A 
protein’s pI is determined by the type and number of acidic and basic residues it contains.107, 108 
The second dimension in 2D-GE separates proteins based on their mass and is usually performed 
in a SDS gel (SDS-PAGE). 2D-GE has difficulty resolving large proteins, or those with extreme 
pI or hydrophobicity, and suffers from lack of reproducibility.109  
Liquid chromatography (LC) is a technique used to separate components on a stationary 
phase using a liquid mobile phase. Reversed-phase high-performance liquid chromatography 
(RP-HPLC) separates proteins and peptides by hydrophobicity.110 It is one of the most powerful 
and commonly used liquid chromatography techniques.111 Commonly used hydrocarbon ligands 
for reversed-phase resins include C4 and C18.
110 C4 is commonly used for polar proteins and C18 
is most used for peptides.  
Ultra performance liquid chromatography (UPLC) uses smaller particles as well as high 
speed and peak capacity (the number of peaks that can be resolved per unit time).112 Compared 
to conventional HPLC columns which are packed with 3.5 to 5 µm particles, UPLC columns are 
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packed with 1.7 µm particles.113 Smaller particles shorten the analyte’s diffusion path which 
improves separation efficiency, speed, and resolution.114, 115  
Ion exchange is another form of chromatography which involves the separation of 
proteins and peptides based on their charge.110 A cationic or anionic resin is used and proteins or 
peptides of opposite charge are retained due to charge attraction. Hydrophilic-interaction 
chromatography separates proteins based on their hydrophilic properties; hence the stationary 
phase is polar.116 Another separation technique is affinity chromatography, which separates 
proteins and peptides based on their specific ligand-binding affinity.110 There are two fractions 
collected from affinity separation, the unbound and the bound proteins and peptides. The 
analyses and detection of low abundant proteins, primarily in plasma, can be difficult due to the 
presence of high abundant proteins such as albumin, immunoglobulins, and transferrin.117 
Therefore, affinity-based approaches can be used to remove high abundant proteins or low 
abundant proteins can be enriched.109    
Due to the complexity of the protein samples, one-dimensional separation techniques are 
usually insufficient and multi-dimensional separations are employed. In multi-dimensional 
separation, two or more separation techniques are coupled together to improve the resolving 
power. These separation techniques are orthogonal to one another.   
1.2.4 Mass Spectrometry 
Mass spectrometry (MS) is an analytical technique used for measuring the mass and 
chemical structure of molecules and is widely used for proteome analysis. A variety of ionization 
techniques can be used for mass spectrometry but the most commonly used techniques for the 
analysis of biomolecules are electrospray ionization (ESI)118 and matrix assisted laser desorption 
ionization (MALDI).119-121 MALDI uses a matrix that absorbs laser energy and aids in ionization 
of the analyte. The ions generated are typically singly charged. ESI can also be used to analyze 
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biomolecules. Unlike MALDI, its ions are produced from solution. After the ions are formed 
they are transferred into a mass analyzer by an electric field where they are separated according 
to their mass-to-charge ratio. Two stages of mass separation can be coupled (either in space or in 
time) to obtain additional information of the sample being analyzed which is known as tandem 
mass spectrometry (MS/MS).122 Tandem mass spectrometry is used to determine peptide 
sequences from proteins.83 A peptide is separated from a mixture of peptides in the first stage of 
mass spectrometry and dissociated by collision with an inert gas. The generated fragments are 
separated in the second stage of mass spectrometry.83, 123  
There are three MS proteome analysis approaches: 1) bottom-up proteomics, 2) shotgun 
proteomics, and 3) top-down proteomics. In the bottom-up approach the protein mixture is 
separated usually by 1 or 2-dimensional electrophoresis and the individual protein bands or spots 
are cut and digested with an enzyme such as trypsin resulting in peptides. The peptides are 
analyzed by mass spectrometry using peptide mass fingerprinting or tandem mass spectrometry 
(MS/MS) to create sequence tags for database searching.124-126 Some of the major advantages of 
using the bottom-up approach are the ability to obtain high-resolution separations and a 
comprehensive coverage of proteins. It’s the most widely used technique in proteomics,127 hence 
several bioinformatics tools are available. In addition, proteins can be separated in a complex 
mixture before digestion so there is a greater chance of identification. The drawback of this 
approach is the limited dynamic range128 and difficulty separating membrane proteins.129, 130  
In shotgun proteomics, a mixture of intact proteins is enzymatically digested and 
separated using strong cation-exchange chromatography (SCX) followed by reversed-phase 
liquid chromatography (RPLC).109, 131 The separated peptides are subjected to tandem mass 
spectrometry and database searching.131 A major advantage of this technique is that thousands of 
proteins can be identified in a single analysis and the technique is better suited to membrane 
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proteins. However, limitations of this technique includes the need for complex mixtures to be 
purified prior to separation,132 limited dynamic range,63 and bioinformatics challenges to identify 
peptide and protein sequences from a large number of acquired spectra.63 
In the top-down approach, intact proteins are separated by gel electrophoresis or HPLC 
before being introduced into the mass spectrometer.124, 126 The mass of the protein is measured 
and tandem mass spectrometry is used to generate sequence tags (a short sub-sequence of a 
peptide sequence) for database searching. Alternately, de novo sequencing (an approach to 
determining a peptide sequence without prior knowledge of the sequence) can be performed.126 
Top-down sequencing can be used to locate and characterize post-translational modifications, 
determine the complete protein sequence, and minimize time-consuming preparation steps such 
as separation and digestion procedures. Conversely, spectra generated by multiply charged 
proteins can be very complex and bioinformatics tools still needs more developing for protein 
identification. In addition, top-down sequencing does not work well with intact proteins greater 
than 50 kDa. 
Separation can also be performed in the gas phase using ion mobility mass spectrometry 
(IM-MS).133-135 Ion mobility is a gas-phase technique that separates ions based on their ability to 
migrate through a gas in the presence of an electric field.133, 134 The mobility is dependent on the 
collision cross section of the ion. An ion mobility spectrometer consists of a gas filled cell where 
ions travel under the influence of an electric field.133 Ions with larger diameters undergo more 
collisions with the buffer gas, hence their passage through the drift cell is slower, whereas 
smaller molecules undergo fewer collisions and pass through the drift cell more rapidly.133 When 
coupled with MS both the mass to charge and size to charge ratio of the ions can be determined. 
Both MALDI and ESI can be used as an ionization source for IM-MS.136 However, many IM 
studies reported in literature of peptides and proteins describe the use of an ESI source coupled 
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with IM.137-139 IM can also be coupled with tandem MS for additional peptide and protein 
information.140 
IM-MS separations can obtain comparable resolutions to HPLC and CE.134 LC-MS, a 
more commonly used proteomics technique is advantageous in that it increases the dynamic 
range,141 however, coupling LC to MS limits optimization of LC and LC can take minutes to 
hours for separation which limits sample throughput.142 IM offers two major advantages over LC 
techniques; it reduces separation time and the post-ionization separation provides information on 
the product.134 Another major advantage of IM-MS is that it adds two separation dimensions for 
different chemical classes,143, 144 for example peptides, DNA, oligonucleotide and lipids or 
conformational classes such as α-helix and random coil.145 However, IM-MS has its 
shortcomings for proteomic applications, specifically poor sensitivity and limited peak 
capacity.134 Despite the limitations of IM-MS for proteomics it has still been proven to be a 
useful method for proteomics,134 metabolomics,146 and glycomics.147 
1.2.5 Protein Bioinformatics 
Bioinformatics is the approach used to analyze large numbers of genes and proteins148 
and is important for the elaboration of mass spectrometry data due to the large amount of data 
produced.149 It is used in proteomics to provide functional analysis and mining of data sets.148 
Peptide and protein data can be interpreted via peptide mass fingerprinting, database searching, 
or de novo sequencing. 
Peptide mass fingerprinting (PMF) is a high-throughput protein identification method.150 
In this method the protein is purified and cleaved using an enzymatic or chemical approach to 
generate peptides. The peptides are analyzed via ESI or MALDI mass spectrometry and a 
peptide mass fingerprint (the masses of the intact peptides in the sample) is obtained. The mass 
fingerprint is compared to theoretical cleavages of protein sequences in databases and the protein 
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matches are scored based on the best match.150, 151 Several programs have been developed for 
peptide mass fingerprinting including MassSearch, Mowse, MS-FIT, PepMAPPER, PepSea, 
PeptideSearch, ProFound and PeptIdent.152 Peptide mass fingerprinting will only yield hits for 
proteins that are in a sequence database.   
An alternate approach to database searching is mass spectral matching. This entails 
matching the experimental spectrum to a library of previously obtained MS/MS data.153 This 
method is a fast and precise means to identifying peptides whose proteome has been previously 
identified. Its major limitation is its inability to be used for identifying or discovering new 
peptides. 
Another approach for database searching compares experimental spectra to theoretical 
spectra to identify peptides in the protein database. Theoretical tandem mass spectra are 
produced from fragmentation patterns that are known for a specific series of amino acids. Search 
engines that are used for database searching includes Mascot,154, SEQUEST,155 X!TANDEM, 156 
Open mass spectrometry search algorithm (OMSSA),157 SONAR,158 ProbID,159 
PeptideProphet160 and OLAV-PMF.161 Two commonly used search engines include Mascot and 
SEQUEST. SEQUEST uses a cross-correlation score to match hypothetical spectra to 
experimental spectra155 whereas Mascot uses a probability score that indicates the probability of 
whether or not a spectral match was random.154 When some commonly used search engines were 
compared, including SEQUEST and Mascot, Mascot proved to be able to better discriminate 
between a correct and incorrect hit as compared to SEQUEST.162 An overall evaluation showed 
that Mascot outperformed the other algorithms used in the study, which included PeptideProphet, 
Spectrum Mill, SONAR and X!TANDEM. 
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Mascot is based on probability scoring and the lowest probability is the best match. The 
match significance criteria depend on the size of the database. The score is reported as -10log 
(P), where P is the probability. Hence, the best match has the highest score.  
Database searching offers several advantages including high-throughput, robustness and 
well annotated proteins (detailed information on each protein). Despite these advantages there 
are also some disadvantages that are associated with database searching including false positive 
identification due to selection of background peaks, unidentified peptides due to post 
translational modifications, scoring a longer peptide that may be from a lower quality MS/MS 
spectrum (low signal-to-noise ratio)  with a higher score than a shorter peptide from a higher 
quality MS/MS spectrum (high signal-to-noise ratio), and, most importantly, it is impossible to 
identify a peptide that is not part of a protein in the database.163  
De Novo sequencing is an approach to identifying peptides without database searching, 
for example for a species whose genome has not been previously sequenced. It is also used to 
identify post-translational modifications. The de novo approach determines peptide sequences 
using information such as the type of fragmentation method, for example collision induced 
dissociation (CID),164 electron-transfer dissociation (ETD),165 or electron-capture dissociation 
(ECD),164, 166 the type of enzyme used, as well as any chemical modifications. Some commonly 
used de novo sequencing programs are PEAKS167 Mascot Distiller97, Lutefisk,168 PepNovo,169 
and SHERENGA.170 Tandem mass spectrometry data can also be searched against expressed 
sequence tag (EST) databases to identify peptides and proteins for organisms without complete 
genomes. ESTs are nucleotide sequences (200 to 500 nucleotides long) that are generated by 
sequencing either one or both ends of an expressed gene originating from specific tissues.171  
These nucleotide sequences are translated into protein sequences for protein identification from 
tandem mass spectra. 
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Under CID, peptides fragment along the peptide backbone and fragment ions generated 
from the N-terminus of the peptide are labeled a, b, and c, whereas fragments generated from the 
C-terminus of the peptide are labeled x, y, and z.172 De novo spectra generated from low energy 
CID gives only partial peptide ion coverage because of its backbone cleavage specificity; in low 
energy CID spectra c, x, z and a-type fragment ions are not observed.172 Hence, it is usually 
beneficial to collect peptide spectra from other fragmentation methods such as ETD or ECD. 
Some of the limitations associated with CID include overlapping fragment ion peaks (which can 
cause incorrect peak assignment), low signal for some of the ions in the CID spectra, difficulty 
identifying post-translational modifications, and the inability to differentiate between the amino 
acids leucine and isoleucine.163 The ETD and ECD techniques can be used which can 
differentiate between leucine and isoleucine as well as identify post-translational modifications. 
ECD also produces less specific backbone cleavage as compared to CID; therefore, more 
extensive sequence information can be obtained on proteins.164 However, a limitation of ETD 
and ECD is their inability to produce good quality data with shorter peptides, such as those 
generated from tryptic digests.163 
Basic local alignment search tool (BLAST) is a search algorithm that is used to compare 
sequence similarities between experimentally determined nucleotide or protein sequences with 
nucleotide or protein databases.173 This approach is useful for the identification of proteins from 
organisms that have unsequenced genomes.174, 175 A BLAST alignment pairs each amino acid in 
the queried sequence to those in another sequence from a protein database.  BLAST begins a 
search by indexing short character strings (amino acid sequences) within the peptide query by 
their starting position in the query. The “word size” (length of the amino acid sequence) for a 
protein-to-protein sequence comparison is typically three. The BLAST software then searches 
the database to look for matches between the indexed “words” from the queried peptide to 
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character strings within the sequence in the database. Whenever a word match is found, BLAST 
then extends the sequence (using the database sequence) in the forward and backward direction 
to create an alignment. The BLAST score value increases as long as the alignment matches and 
will begin to decrease once it encounters mismatches.176, 177 
The BLAST results are quantified by comparing them to the expect value (E-value). The 
E-value threshold represents the number of times a good match is expected to occur by chance 
and is proportional to the size of the database. BLAST determined E-values that are greater than 
the threshold E-value are considered significant. The higher the similarity between the queried 
sequence and the sequence in the database the lower the E-value is. This can be seen in Equation 
1-1,  
	 ∗ ∗ ∗   EQUATION 1-1 
where K is a constant (scaling factor), m is the length of the query sequence, n is the length of 
the database sequence, λ is the decay constant from the extreme value distribution (scales for the 
specific scoring matrix used)  and S is the similarity score.176  
1.3 Research Objectives 
The objective of this research is to characterize the biological molecules isolated from the 
Alligator mississippiensis immune system and identify antimicrobial molecules. To achieve this 
goal, the specific aims of the project were (1) to isolate and characterize the proteins of the 
leukocytes, (2) to purify and identify antimicrobial peptides from whole blood, and (3) to isolate 
and determine the primary sequence of lectin from the serum. The first set of experiments, 
described in Chapter 3, used gel electrophoresis and multidimensional gel electrophoresis to 
separate a mixture of isolated leukocyte proteins for mass spectrometry detection and sequence 
identification. A second set of experiments, described in Chapters 4 and 5, used a combination of 
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separation techniques for purification of a novel antimicrobial peptide. Although antimicrobial 
peptides have been identified and characterized in numerous organisms, antimicrobial peptides 
have not yet been identified in alligators. For the third set of experiments described in Chapter 6, 
a new lectin from Alligator missisissippiensis was identified using de novo sequencing with 
different enzymatic digests and characterized. Chapter 7 describes deglycosylation approaches 
and compares sample clean-up procedures that can be applied to glycoproteins for mass 
spectrometry analysis.    
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CHAPTER 2. EXPERIMENTAL* 
 
This chapter contains a description of the instruments and methods used for analyzing 
peptides and proteins isolated from the blood of alligators. A summary of the instruments and 
techniques used for this research, including gel-based protein separations, liquid 
chromatography, ion mobility, mass spectrometry, and proteomic bioinformatics is described. A 
detailed description of the experimental parameters and procedures used for the separation 
techniques as well as the electrospray ionization time-of-flight (ESI-TOF), matrix-assisted laser 
desorption ionization tandem time-of-flight (MALDI-TOF/TOF) and electrospray ionization-
quadrupole-time-of-flight (ESI-QTOF) mass spectrometers is given.  
2.1 Blood and Leukocyte Collection 
Adult alligators were captured at night by boat at J. D. Murphree State Wildlife Refuge in 
Port Arthur, Texas, with the use of a spotlight and a cable harness and housed at the Rockefeller 
State Wildlife Refuge in Grand Chenier, Louisiana. The animals were kept in fiberglass-lined 
concrete tanks approximately 5 m long and 2 m wide, with 50% dry bottom and 50% water of 
approximate 0.2 m depth. The temperature was maintained at 31 ºC. Several alligators up to 1.5 
m in length were housed in a single tank. The alligators were fed formulated dry pellets four 
times per week and the cages were cleaned five times per week.  
 Blood samples were collected from the supravertebral branch of the internal jugular vein 
using a heparinized 38 mm long 18 gauge needle and a 60 mL syringe178, 179 and transferred to 
250 mL plasma bottles containing 25 mL of 500 mM EDTA. This method of blood collection 
has been approved by the McNeese State University Animal Care and Use Committee and is 
routinely used to collect blood from wild and captive adult alligators (See Appendix D). 
  *Portions reprinted by permission from the Elsevier. The work reported in this chapter has 





 Leukocytes were isolated from the whole blood by differential sedimentation. Whole 
blood samples were mixed with one volume of 5% dextran and the erythrocytes were allowed to 
settle for approximately two hours. The leukocytes were separated manually from the top phase 
using a transfer pipette.1   
 The leukocytes were centrifuged for 15 min. at 1500 g and the leukocyte pellet was 
resuspended in approximately one volume of 10% acetic acid and stored at -80ºC until needed. 
Prior to analysis, the leukocyte pellets were homogenized in a Dounce homogenizer and then 
centrifuged at 20,000 g for 30 min. The clear supernatant was transferred to 1 kDa concentrator 
tubes (Centriprep, Millipore Corp., Billerica, MA) and centrifuged at 5000 g to concentrate the 
sample and remove the acetic acid. The concentrated extract and precipitate were resuspended in 
10 mL of 0.1% acetic acid. The resuspended extract was centrifuged at 20,000 g and the clear 
supernatant was used in the gel electrophoresis and HPLC analysis.  
2.2 Liquid Chromatography 
In this work, reversed-phase liquid chromatography was used. Both capillary and nano 
capillary high performance liquid chromatography (HPLC) as well as nano ultra performance 
liquid chromatography (UPLC) were used.  
2.2.1 Nano HPLC 
Nano capillary HPLC (nanoLC) uses columns that have an inner diameter (ID) between 
50 and 100 µm and flow rates below approximately 120 nL/min.180 In this work, nanoLC was 
coupled to the mass spectrometer described in Section 2.6.4. Typical columns used for nanoLC 
have lengths of 50-150 mm with 3-5 µm particle diameters. For improved chromatographic 
separation, acids, including trifluoroacetic acid (TFA) and formic acid (FA), are added to the 
solvents at 0.1%. TFA is best for offline LC because it provides higher peak capacity with 
narrower peak width. However, if the LC is coupled online with the mass spectrometer, FA is 
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preferred because the high surface tension of the TFA solution makes spray formation difficult 
and trifluoroacetate can form strong ion pair complexes with peptide cationic sites causing signal 
suppression.181 
The LC separations were performed on a LC Packings/Dionex capillary and nano HPLC 
system. The HPLC system is equipped with a low pressure mixing system, micropump, flow 
splitting unit that allows flow rates from 50 nL/min to 200 µL/min, a sample injector, and UV 
detector. A Vydac C18 75 µm ID × 150 mm, 5.0 µm column was used. The solvents were water 
in 0.1% FA and acetonitrile in 0.1% FA. The column flow rate was 200 nL/min and a linear 
gradient was used for separation. 
2.2.2 Capillary HPLC 
Capillary HPLC is separation on a column that has an ID between 100 and 300 µm and 
flow rate that is several µL/min. A capillary HPLC (Agilent 1200 series) was used both online 
with the Agilent mass spectrometer (see Section 2.6.3 below) and offline with a photodiode array 
(PDA) detector over a wavelength range between 190 and 400 nm. The capillary HPLC is 
equipped with a binary and gradient pump, diode array detector, autosampler and thermostat. In 
this work, a C18 2.1 mm ID × 50 mm, 5.0 µm column (Zorbax) and a C18 4.6 mm ID × 250 mm, 
5.0 µm column (Vydac) were used. The solvents were water in 0.1% FA and acetonitrile in 0.1% 
FA. The column flow rate was 300 µL/min and a linear gradient was used for separation. 
2.2.3 Nano Ultra Performance Liquid Chromatography  
Nano ultra performance liquid chromatography (nano UPLC) uses columns that typically 
have an ID between 75 and 1000 µm and flow rates between 200 nL/min and 100 µL/min. A 
UPLC system (Waters nanoAcquity) was used online with the Waters Synapt instrument 
described in Section 2.6.5. The system is equipped with a binary solvent manager, sample 
manager, a column heating compartment and a UV detector. In this study, an C18 column 
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(Acquity) packed with 1.7 µm particles, 5 cm long × 2.1 mm ID was used. The samples were 
diluted in 0.1% FA and eluted using a gradient with 3–85% 0.1% FA in acetonitrile (v/v) for 32 
minutes. The column flow rate was 500 nL/min and 214 nm UV absorption was recorded. 
2.3 Ion Mobility 
 Another separation technique used in this work was ion mobility (IM). The ion mobility 
cell was built into a Q-TOF mass spectrometer (Waters Corporation), details of this mass 
spectrometer are found in Section 2.6.2. The peptide samples were diluted in 0.1% FA and 
injected on the UPLC system at a flow rate of 500 nL/min. The peptides were separated using a 
gradient of 3–40% B over 30 minutes. Solvent A was 95% water and 5% acetonitrile containing 
0.1% FA. Solvent B was 80% acetonitrile and 20% water containing 0.1% FA. The peptides 
were ionized using a nano-electrospray source and analyzed via a quadrupole mass analyzer 
before being introduced to travelling wave ion mobility cell. In travelling wave ion mobility 
spectrometry (TWIMS) pulsed voltage waves guide the ions through the drift cell via stacked 
ring electrodes.182 As the waves move, the ions are pushed for a short distance before moving 
over the wave. Smaller ions undergo fewer collisions with the buffer gas so travel faster in the 
traveling wave’s gradient, whereas larger ions undergo more collisions with the buffer gas 
slowing them down therefore requiring a longer time to be moved by the traveling waves.140, 182 
A pressure of 0.5 bar of nitrogen was maintained in the IM cell. Each set of experiments was run 
in triplicate. 
2.4 Gel Electrophoresis 
 Both one- and two-dimensional gel electrophoresis was used to separate protein mixtures 
prior to digestion and mass spectrometry analysis. One-dimensional gel electrophoresis was 
performed using a small format cell (BioRad mini-PROTEAN). The main components of this gel 
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The sample buffer system used in this work was a discontinuous buffer system that 
incorporated sodium dodecyl sulphate (SDS) and a reducing agent, β-mercaptoethanol, in the 
buffer. SDS is an anionic detergent that denatures and binds to proteins. The polypeptides 
become rod-like in shape with a negative charge.184 Because all the proteins have the same 
charge, they separate according to their molecular mass. The β-mercaptoethanol is used to reduce 
the disulfide bridges in the proteins so that they can assume the random-coil configuration 
required for optimum separation.106 
To resolve proteins with similar molecular weights, two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) was performed. 2D-PAGE is a powerful proteomics separation tool 
as it is capable of separating thousands of proteins in a typical cell.185 The first dimension, 
isoelectric focusing (IEF) was performed in an isoelectric focusing cell (Bio-Rad Protean IEF). 
IEF is usually performed in an immobilized pH gradient strip.186 The pH gradients used in this 
work were 3–10 and 3–6. Prior to the second dimension, the proteins separated by IEF 
underwent an equilibration step. The proteins were reduced and alkylated using DTT and 
iodoacetamide and SDS was added to give the proteins a negative charge. This allowed the 
separation based on size in the second dimension. The second dimension was performed using 
the Bio-Rad Protean II 2-D electrophoresis cell. 
The gels were stained to visualize the proteins. Several stains are commercially available: 
Coomassie blue R-250, Bio-safe Coomassie, Sypro ruby fluorescent stain, and silver stain.106, 185 
The choice of stain used depends on several factors such as sensitivity, ease of use, and type of 
imaging equipment available. Coomassie R-250 stain (wool dye with a red hue) is the least 
sensitive: it requires 40 ng of protein for detection.185 Bio-safe Coomasie stain is prepared with 
Coomassie G-250 (wool dye with a green hue) and can be used to detect as little as 10 ng of 
protein.185 The most sensitive stains are Sypro ruby fluorescent and silver stains which both can 
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be used to detect as little as 1 ng of protein.185 In this work, Bio-safe Coomasie or silver stains 
were used. Both stains are mass spectrometry compatible, meaning that the stains have high 
sensitivity for protein detection while minimizing crosslinking of the protein to the gel, which 
can inhibit recovery for mass spectrometry.187  
There are also specific stains that can be used for detecting modified proteins such as 
glycoproteins. The most commonly used methods for detecting glycoproteins in polyacrylamide 
gels involves detection by periodic Schiff (PAS) staining using chromogenic detection, for 
example acid fuchsin dye.188 Another approach utilizes Pro-Q Emerald 300 fluorescent dye, that 
links to glycoproteins using periodic Schiff conjugation.189 During the staining process the 
glycols in the glycoproteins are oxidized to aldehydes with periodic acid. The dye then reacts 
with the aldehydes on the glycoproteins and a fluorescent conjugate is generated.189 This stain 
can be used to detect as little as 0.5 ng of glycoprotein and is compatible with mass spectrometry 
analysis. This glycoprotein stain was used in the initial characterization of lectin proteins studied 
in this work. 
Gel images were captured using a camera (Gel Doc XR System with Quantity One 1-D 
analysis software, BioRad) which is capable of imaging Coomassie stained, silver stained, and 
fluorescent gels.  
2.5 Edman Sequencing 
Edman sequencing involves labeling the N-terminal residue of a protein or peptide with 
phenyl isothiocyanate. The peptide bond adjacent to the modified residue is cleaved via mild 
acid hydrolysis, leaving the rest of the protein intact. The terminal amino acid residue that has 
been modified is identified by liquid chromatography. The process is repeated successively for 
the residues in the peptide sequence until a complete sequence is determined.69 Protein bands 
were excised from SDS polyacrylamide gels and submitted to the University of Texas Medical 
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Branch, Protein Chemistry Core laboratory for N-terminal sequencing using a protein sequencer 
(LC 494, Applied Biosystems, Foster City, California). 
2.6 Proteolysis of Isolated Proteins 
 Proteolysis generates peptides from proteins using either enzymatic or chemical cleavage. 
Proteolysis experiments were performed for peptide sequencing. Digestions were performed both 
in-gel and in-solution. Prior to proteolytic digestions, reduction and alkylation was performed to 
reduce the disulfide bonds for more efficient digestion. For reduction and alkylation a reaction 
buffer containing 25 mM NH4HCO3 was mixed with 10 mM dithiothreitol (DTT). To a vial 
containing approximately 100 µg of lyophilized protein in 25 mM NH4HCO3, 10 µL of DTT 
solution was added and the sample mixture was heated for one hour at 57ºC. The vial was 
removed from the heat block and allowed to cool to room temperature and 40 µL of 55 mM of 
iodacetaminde (IA) solution was added and incubated at room temperature in the dark for 30 
minutes.  
Several enzymatic and chemical proteolytic agents were used: trypsin, α-chymotrypsin, 
Glu-C, Asp-N, Lys-C, cyanogen bromide (CNBr), and formic acid. The enzymatic digestions 
were performed in a heat block at 37ºC, the CNBr digestions were performed at room 
temperature in a fume hood, and the FA digestions were performed at 37ºC. 
 For the enzymatic digestions, a 0.2 µg/uL solution of trypsin was prepared in 1 mM HCl 
and stored for a maximum of four weeks at -20ºC. The reaction solution contained 1 µl of trypsin 
(0.2 µg), 9 µL of 40 mM NH4HCO3 and 9% acetonitrile by volume. For enzymatic digestions 
using Lys-C, Asp-N and Glu-C, the preparations were as follows:  0.1 µg/µL of Lys-C in a 1:20 
ratio (v/v), 0.04 µg/µL of Asp-N in a 1:50 ratio and 0.1 µg/µL of Glu-C in a 1:20 ratio. For 
CNBr digestions a 1 M solution was prepared in acetonitrile (ACN) and stored at -20ºC. The 
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calculates the probability that the observed match between the experimental data and a protein 
sequence is random.152 
The second approach, de novo sequencing with database searching, is necessary for 
organisms that do not have a large number of proteins in the sequence database. One source for 
protein database information is the genome sequence of an organism. Protein databases can be 
constructed using the translated protein sequence. Three de novo sequencing software tools were 
used in this work:  Mascot Distiller,197 PEAKS,167 and BioTools. Mascot Distiller (Version 2.4, 
Matrix Science, Boston, MA) generates peak lists for de novo sequencing. The sequencing 
software fits each peak in the mass spectrum to a hypothetical amino acid combination of the 
same mass. A list of amino acid combinations corresponding to each peak is generated from the 
best fit data.197 
 The second software used, PEAKS (Version 5.2, Bioinformatics Solutions, Waterloo, 
ON), applies four processes: preprocessing, candidate computation, refined scoring, and global 
and positional confidence scoring. First, the raw MS/MS data is smoothed and deconvoluted 
from doubly and triply charged ions to singly charged ions, and peak centering (taking the 
centroid of the first peak of the isotope distribution and removal of the other isotopic peaks) is 
performed. Second, sequences of all possible combinations of amino acids for the selected 
precursor mass are determined. The fragment ion series a, b, c, x and y are used to determine the 
peptide sequences. Next, the best sequences are scored using a stringent scoring scheme where 
the ion mass error tolerance is stricter. Last, PEAKS generates a confidence score for each of the 
top-scoring peptide sequences.167  
 BioTools (Version 2.2, Bruker Daltonics, Billerica, MA) uses MS/MS spectra from 
MALDI-TOF/TOF to generate sequence tags of various lengths and scores. Proposed sequences 
are calculated from the masses in the MS/MS spectrum using sequence tags. Sequence tags are 
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produced using the fragment masses and information added by the user to the software, such as 
terminal amino acids and enzymes used. The suggested sequence tags are then extended to 
produce a list of all peptide sequences that could fit the MS/MS data. The sequences are scored 
based on the number of matched ions. Several candidate sequences may be calculated with 
similar scores; in this case the proposed sequences needs to be manually fitted to the MS/MS 
data. However, if the peptide sequence produced complete fragmentation in the MS/MS 
spectrum one peptide sequence may be the best fit.198 
The peptide sequences found by de novo sequencing are used in protein database 
searches in order to find proteins with similar sequences. The protein databases used in this work 
were the National Center for Biotechnology Information (NCBI) database, Mass Spectrometry 
Protein Sequence Database (MSDB), and Swissprot. NCBI is a non-identical protein and nucleic 
acid database that has sequences taken from multiple sources including Swissprot, the Protein 
Data Bank, and translations from annotated coding regions in the GenBank. One of the major 
advantages of NCBI is that it is frequently updated; therefore, this database was used the most in 
this work. MSDB is also a non-identical protein database that comprises a number of other 
protein databases; however, it is not updated as frequently. Swissprot is a non-redundant protein 
database that provides a high level of annotations such as protein function and post-translational 
modifications. 
Proteins were also determined from peptide sequences using Basic Local Alignment 
Search Tool (BLAST). BLAST is used for comparing high-scoring segment pairs (HSP) in 
nucleotide or protein sequences to sequences in nucleotide or protein databases. HSP is a region 
between a pair of sequences, either nucleotide or amino acid, that share high level of 
similarity.174, 199 BLAST can also provide evolutionary relationships for the species under 
consideration, which shows how two species are related with respect to their evolutionary 
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descent. For this work, BLAST was used to compare peptide sequences generated from alligator 
leukocyte and lectin proteins to proteins in the protein database. For BLAST searching, Swiss-
Prot and NCBI databases were used to search peptide sequences using all taxonomies. The 
expect threshold was set to 20,000 and the score matrix used was PAM30.  
To look for protein sequence similarities DIALIGN and CLUSTALW software were 
used. The DIALIGN software uses both local and global alignment features by either aligning all 
residues in each sequence or aligning only residue segments that are closely related.200 
CLUSTALW allows for the alignment of multiple protein sequences in order to determine 
similarities and differences.201  
2.8 X-Ray Crystallography 
 In this work, small molecules were isolated from alligator leukocyte extracts and 
submitted for structural characterization using an X-ray diffractometer with charge coupled 
device (CCD) area-detector (Bruker Kappa Apex II, Madison, WI, USA). The X-ray 
diffractometer provides accurate and precise measurements of the entire three-dimensional 
structure of a molecule, including the bond angles and distances as well as crystal structure.    
2.9 Deglycosylation  
 Deglycosylation is the removal of a sugar from a glycogen, especially a glycoprotein. 
The oligosaccharides can be removed using either an enzyme or a chemical reagent. There are 
several enzymes available for deglycosylation of N- and O-linked oligosaccharides; these 
include peptide-N-(N-acetyl-β-glucosaminyl)asparagine amidase (PNGaseF), endo F and endo H 
(endo-β-N-acetylglucosaminidases F and H) for removal of N-linked oligosaccharides,202 as well 
as O-glycanase for removal of only galactose-N-acetylgalactosamine (Gal-GalNAc) O-linked 
oligosaccharides.203 A commonly used enzyme is PNGaseF, which was used in this work. 
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Aldrich) that was previously autoclaved at 120ºC for 20 minutes. The TSB was prepared using 
3.0 mg of TSB medium dissolved in 100 mL of nanopure water. A 20 µL volume of bacteria was 
added to 15 mL of the TSB medium containing 1% (wt/vol) low-electroendomosis-type agarose 
(Sigma Aldrich). The previously prepared TSB medium containing agarose (agar) was heated in 
a water bath at 42ºC before use. The agar was poured into an agar plate to form a uniform layer 
and allowed to solidify. Evenly spaced holes were punched using a sterilized pipette tip 
connected to a vacuum for suction to create wells. Added to individual holes was 5 µL of control 
sample (0.1% acetic acid) and polymyxin B, which was used as the standard and isolated peptide 
samples (antimicrobial peptides). The samples were added in triplicate and the plates were 
incubated for 3 hours at room temperature followed by an overnight incubation at 37ºC. After 
incubation, the size of the clear zone around each well was measured. The size of a clear zone 
around the well indicates the antimicrobial activity of the peptides. The absence of a clear zone 
indicates no antimicrobial activity.   
2.11 Reagents and Chemicals 
 Ammonium bicarbonate and cyanogen bromide (CNBr) were obtained from Sigma 
Aldrich (St. Louis, MO). The chemicals trifluoroacetic acid (TFA) and acetic acid were 
purchased from Fisher Scientific. The MALDI matrix α-cyano-4-hydroxycinnamic acid (CHCA) 
was obtained from Sigma and 3, 5-dimethoxy-4-hydroxycinnamic acid (sinapic acid), DHB, and 
sDHB were obtained from Fluka. Trypsin, α-chymotrypsin, endoprotease Asp-N from 
Pseudomonas fragi, endoprotease Glu-C from Staphylococcus aureus, and endoprotease Lys-C 
from Lysobacter enzymogenes were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Dithiothreitol (DTT), iodacetamide, HPLC grade acetonitrile, formic acid, and glu-fibrinopeptide 
standards (Sigma-Aldrich) were used without further purification.  
45 
 
Laemmli sample buffer, 10× SDS-tris-glycine buffer, β-mercaptanol, tris-HCl gradient 
gel, Coomassie blue stain (Bio-Safe), and molecular weight marker standards were purchased 
from Bio-Rad (Hercules, CA, USA). Dithiothreitol, iodacetamide, and glu-fibrinopeptide were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Trifluoromethanesulfonic acid (TFMS), 
pyridine, and toluene were purchased as a kit from Prozyme (Hayward, CA, USA). 
The bacteria strains used in this study were obtained from American Type Culture 
Collection (ATCC) (Manassas, VA). The following American Type Culture Collection (ATCC) 
bacterial strains were used: Escherichia coli (35218), Shigella flexneri (12022), Enterobacter 
cloacae (23355), Klebsiella oxytoca (33496), Staphylococcus aureus (51153), and 
Staphylococcus epidermidis (29887). Trypticase soy broth was purchased from Voigt Global 




CHAPTER 3. PROTEOME ANALYSIS OF THE LEUKOCYTES FROM THE 
AMERICAN ALLIGATOR (ALLIGATOR MISSISSIPPIENSIS) USING MASS 
SPECTROMETRY* 
 
The purpose of the research described in this chapter was to investigate proteins related to 
the alligator immune system. This chapter describes the use of mass spectrometry in conjunction 
with gel electrophoresis and liquid chromatography to determine peptide sequences from 
American alligator (Alligator mississippiensis) leukocytes and to identify similar proteins based 
on homology. Proteins from leukocyte extracts were separated using two-dimensional gel 
electrophoresis and the major bands were excised, digested, and analyzed with on-line nano LC 
MS/MS to generate peptide sequences. The sequences generated were used to identify proteins 
and infer their function based on similarity to previously identified proteins. Similar proteins 
were identified based on matching two or more peptides from the alligator protein to similar 
proteins by searching against the NCBI database using Mascot and Basic Local Alignment 
Search Tool (BLAST). For those proteins with only one peptide matching, the phylum of the 
organism corresponding to the matching protein was considered.  
3.1 Introduction 
A large amount of anecdotal evidence exists to suggest that crocodilians are resistant to 
bacterial, fungal and viral infections208-210 and have the ability to fight a variety of diseases that 
may pose human health risks.211, 212 Several studies have shown that the serum of alligators 
exhibit innate immunity against fungi, viruses and various bacterial species.208, 213, 214 It has been 
reported that alligator leukocyte extracts exhibit broad-spectrum antimicrobial activity against 
important human pathogens such as C. albicans, S. faecalis and E. coli.215 It is anticipated that 
elucidation of the alligator blood proteome will aid in identifying these antibacterial, antifungal  
 
*Reprinted by permission of the Elsevier. The work reported in this chapter has been published 




and antiviral peptides believed to be responsible for these properties, which in turn could lead to 
the development of new antibiotics.  
Antimicrobial peptides are typically found in granulocytic leukocytes and are part of the 
innate immune system;216 these antimicrobial peptides are active against a wide range of 
microorganisms such as fungi, bacteria, and viruses.42, 217 Various classes of antimicrobial 
peptides have been isolated from organisms such as bacteria, plants and animals218-220 and are 
characterized by their amino acid sequence and structure.217 The majority of the antimicrobial 
peptides assume linear α-helical or disulfide-stabilized β-sheet conformations24, 217 and are 
typically rich in lysine and arginine; however, some are also rich in proline, histidine or 
tryptophan residues.217 These antimicrobial peptides are typically less than 10 kDa in molecular 
mass and are cationic and amphipathic.24, 217 However, antimicrobial properties have been 
reported for anionic peptides as well as for proteins.24  
Mass spectrometry (MS) and tandem mass spectrometry (MS/MS) in combination with 
multi-dimensional separations have become powerful techniques for peptide and protein 
identification.221, 222 Mass spectrometry-based approaches have been extensively employed for 
the identification and characterization of proteins in blood components such as leukocytes,33, 223, 
224 serum,225 platelets,226, 227 plasma228 and red blood cells.229 For example, online LC MS/MS 
was used to identify 1444 proteins in human serum.230 In other studies, the human blood plasma 
proteome has been characterized using multi-dimensional separation techniques along with 
MS/MS and database searching to identify over a thousand proteins.125, 221, 228  
One of the major challenges in the study of the alligator blood proteome is the limited 
information available regarding the reptilian genome and proteome.33, 231 For proteomic analysis 
of species with limited genomic and proteomic data, de novo sequencing can be used to 
determine protein sequences.175 In de novo sequencing, proteins are isolated and enzymatically 
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digested and the resulting peptides are analyzed by tandem mass spectrometry. The sequence is 
determined by observing the mass differences between fragment peaks in the tandem mass 
spectra which are generated by low energy collision-induced dissociation (CID) of the peptide of 
interest.232 The amino acid sequence can be determined from the N-terminus using the b-ion 
series or from the C-terminus using the y-ion series.233 De novo sequencing has been used to 
identify a number of proteins from species with limited representation in protein databases.234-237 
In the present study, proteins were isolated from the leukocytes of the American alligator 
(Alligator mississippiensis) and separated by one or two dimensional gel electrophoresis. One of 
the challenges in this study is limited proteome data for the alligator hence peptide sequences 
were determined using de novo sequencing with database searching and BLAST search to 
identify similar proteins. Using this approach 43 proteins were identified that represent abundant 
proteins from the alligator leukocyte.  
3.2 Experimental 
 Adult alligators were captured for blood samples and leukocytes were isolated as 
described in Section 2.1. One-dimensional polyacrylamide gel electrophoresis (PAGE) was 
performed using precast 4–20% polyacrylamide gradient gels (8.6 × 6.8 cm) on a small format 
gel electrophoresis system. Leukocyte extracts were dissolved in sample diluting buffer (Tris-
HCl at pH 6.8, containing SDS, glycerol, 2-mercaptoethanol, and bromphenol blue dye) and 
boiled for 3 min prior to loading on the gel. A 10 μl sample volume was loaded on each 
individual lane and in a separate lane, 10 μl of a protein molecular weight standard solution was 
loaded. Electrophoresis was conducted for 1 hr at 100 V using tris–glycine (pH 8.3) as the gel 
running buffer. The gels were then stained overnight with Coomassie blue to aid in visualizing 































g 8 M 










n in 40 mM
s. The tubes





































 V for 20 m
in slab gels
 200 V for 4









 from the ge












 (18.3 × 1











 digest was 

























































 min). For s
ing solutio







 flow rate o





















 of 5 
50 
 
µL/min for an additional 5 min. The peptides were then eluted onto a 75 μm × 15 cm C18 column 
(Biobasic Vydac) and separated using a gradient of 5–40% B over 60 min with a flow rate of 200 
nL/min. Solvent A was 95% water and 5% acetonitrile containing 0.1% FA. Solvent B was 80% 
acetonitrile and 20% water containing 0.1% FA  
The effluent was directed to the quadrupole time-of-flight mass spectrometer (QSTAR 
XL) and ionized using a nano electrospray source at a voltage of 2.5 kV. The mass spectrometer 
was operated in information dependent acquisition (IDA) mode. Three collision energies (25, 38, 
and 50 eV) were selected for fragmentation of the peptides.  
The peptide sequences were generated from MS/MS data using Mascot Distiller software. 
The software determined amino acid sequences from MS/MS data using peak fitting and isotope 
distribution.241, 242 The de novo sequencing results were verified manually.  
De Novo peptide sequences were subjected to database searching using Mascot154 and 
BLAST to find proteins that contain sequences matching with sequences determined by de novo 
sequencing. For BLAST searching, Swiss-Prot and NCBI databases were used to search peptide 
sequences using all taxonomies. The expect threshold was set to 20,000 and the score matrix 
used was PAM30. 
3.3 Results and Discussion 
One-dimensional electrophoresis of the leukocyte extracts revealed six major bands 
ranging from 10 to 75 kDa. The bands marked in Figure 3-1 were excised, digested with trypsin 
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Figure 3-1. A similar strategy was followed for the other labeled bands from Figure 1 as well as 
the protein spots in Figure 3-2.  
For the characterization of peptides and proteins in the gel bands and spots, a three-step 
strategy was adopted. First, the peptides from the digest were sequenced using de novo 
sequencing as outlined above. Second, the sequences were searched against the full SwissProt 
and NCBI databases using Mascot to identify similar proteins. Third, a BLAST search was 
performed for de novo peptide sequences that did not match sequences in the database search of 
step two.  
The Mascot search results are summarized in Table 3-1. The matched peptides shown in 
the table were identified from either the 1D or 2D gel as indicated in the table. The proteins 
included in the table had at least two peptide matches and sequence coverage ranging from 1 to 
37%. The proteins polyubiquitin, hypothetical protein LOC100158585, ubiquitin, hypothetical 
protein, hypothetical protein 4732456N10, endonuclease P1, myosin alkali light chain, myosin 
regulatory light chain, actin, β-actin, actin-2, talin 1, chain A, chicken annexin V {complex with 
Ca2+), alkaline phosphatase-like enzyme, lysozyme C, ras-related protein O-Krev, annexin I, 
hemoglobin and vimentin-4 proteins were identified. 
The de novo sequenced peptides that didn’t match sequences in the database were 
subjected to a BLAST search to identify proteins containing similar sequences. The results of the 
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Table 3-1. Proteins identified in leukocyte extract using Mascot search. Proteins were 
identified by Mascot search of MS/MS data from the leukocyte peptide digest with databases, 
NCBI, MSDB and SWISS-PROT. NCBI accession numbers are provided in table.  
 
Band/Spot No. m/z Charge Matched Peptides Name Function Accession No. Mascot 
Score 
% Coverage 
B1 383.2 +2 MQIFVK Polyubiquitin a BAA23486 340 8 
 520.3 +2 EGIPPDQQR      
 534.8 +2 ESTLHLVLR      
 541.8 +2 TLSDYNIQK      
 508.6 +3 IQDKEGIPPDQQR      
 894.5 +2 TITIEVEPSDTIENVK      
B1 520.3 +2 EGIPPDQQR Ubiquitin a AAG22093 368 32 
 526.3 +2 NSTLHLVLR      
 534.8 +2 ESTLHLVLR      
 541.3 +2 TLSDYNIQK      
 508.6 +3 IQDKEGIPPDQQR      
 895.0 +2 TITNEVEPSDTIENVK      
 902.0 +2 TITKEVEPSDTIENVK      
B3 405.2 +2 LASYLDK Hypothetical 
protein 
LOC100158585 
b NP_001121485 70 3 
 533.3 +2 AQYEDLAKK      
B3 515.3 +2 VLDELTLAR Hypothetical 
protein 
b XP_511487 218 3 
 579.3 +2 QGVEADVNGLR      
 651.4 +2 ALEEANADLEVK      
 453.3 +3 QSVEADINGLRR      
B2 565.8 +2 NLASAVSDLLK      
 871.8 +3 AVSSAIAHLLGEVAQGNENYTGIAAR      
3 639.3 +2 LALDIEIATYR Hypothetical 
protein 
4732456N10 
b NP_808385 187 6 
 651.8 +2 SLNLDSIIAEVK      
 738.4 +2 FLEQQNKVLETK      
1 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 82 11 
 565.6 +3 LANWINEIHGSEIAK      
2 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 255 25 
 565.6 +3 LANWINEIHGSEIAK      
 567.9 +3 VSDSSLSSENHAEALR      
 851.5 +2 VSDSSLSSENHAEALR      
 665.5 +4 FLVHFIGDMTQPLHDEAYAVGGNK      
4 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 72 11 
 565.6 +3 LANWINEIHGSEIAK     
5 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 100 11 
 565.6 +3 LANWINEIHGSEIAK     
7 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 72 11 
 565.6 +3 LANWINEIHGSEIAK     
9 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 381 20 
 565.6 +3 LANWINEIHGSEIAK     
11 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 72 11 
 565.6 +3 LANWINEIHGSEIAK     
12 518.9 +3 LIGGHALSDAESWAK Endonuclease P1 c P24289 98 11 
 565.6 +3 LANWINEIHGSEIAK      
2 498.3 +2 HVLVTLGEK Myosin alkali light 
chain 
d AAA48979 181 30 
 513.2 +2 EAFQLFDR      
 686.8 +2 ALGQNPTNAEVMK      
 575.2 +3 VFDKEGNGTVMGAEIR      
3 518.2 +2 ELLTTMGDR Myosin regulatory e 1805343A 189 18 
                                                            
a
 Removal of damaged or unnecessary proteins and controlling of other cellular processes 
b Unknown function 
c Hydrolyzes only single stranded DNA and RNA without specificity for bases 
d Binds actin and modulates myosin motor function 




 614.8 +2 LNGTDPEDVIR      
 708.3 +2 FTDEEVDELYR      
6 499.7 +2 DLTDYLMK Actin f ACD44586 188 14 
 895.9 +2 SYELPDGQVITIGNER      
14 527.3 +2 TALAPSTMK Actin f ACF32719 79 4 
17 566.7 +2 GYSFTTTAER β-actin f ABB91894 255 37 
 581.3 +2 EITALAPSTMK     
 895.9 +2 SYELPDGQVITIGNER     
 855.4 +3 GYSFTTTAER     
19 473.2 +2 AVFPSIVGR β-actin f CAA27396 81 7 
 652.0 +3 VAPEEHPVLLTEAPLNPK     
33 400.2 +2 AVFPSIVGR Actin-1 f P02578   275 18 
 505.9 +3 IWHHTFYNELR      
 652.0 +3 VAPEEHPVLLTEAPLNPK      
 499.7 +2 DLTDYLMK      
 566.7 +2 GYSFTTTAER      
 581.3 +2 ELTALAPSTMK      
20 473.2 +2 AVFPSIVGR β-actin f ABD48797 139 10 
 505.9 +3 IWHHTFYNELR     
 652.0 +3 VAPEEHPVLLTEAPLNPK     
35 499.7 +2 DLTDYLMK Actin f AAA20641 103 13 
 652.0 +3 VAPEEHPVLLTEAPLNPK     
 855.7 +3 LCYDALDFEQEMQTAASSSSLEK     
36 499.7 +2 DLTDYLMK Actin-2 f P45885 164 14 
 505.9 +3 IWHHTFYNELR     
 652.0 +3 VAPEEHPVLLTEAPLNPK     
 654.3 +3 YPIEHGIITNWDDMEK     
37 505.9 +3 IWHHTFYNELR Actin f Q99023 119 9 
 652.0 +3 VAPEEHPVLLTEAPINPK     
 499.7 +2 DLTDYLMK     
37 378.2 +2 LLLAVVK Chain A, Crystal 
Structures of 
Chicken Annexin V 
























 871.8 +3 AVSSAIAHLLGEVAQGNENYTGIAAR      
9 539.9 +2 GTSIFGLAPSK Alkaline 
phosphatase-like 
i NP_001096792 114 4 
 714.9 +2 DKQNLVQAWQAK      
12 877.4 +2 NTDGSTDYGILQINSR Lysozyme C j LZFER 114 10 























 851.9 +2 GLGTDEDTLNEILASR      
31 578.3 +2 FGGPGTASRPS Vimentin-4 m P24790 151 6 
 627.7 +2 TRSYVTTSTRTYSLG      
 561.2 +2 DLYEEEMR      
12 510.8 +2 VLASFGEAVK Hemoglobin β chain n P02130 131 19 
 560.3 +2 KFIVDLWAK      
 566.7 +2 FHVDPENFK      
                                                            
f Highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells 
g Exocytosis 
h Cytoskeletal protein in lymphocyte involved in connections of major cytoskeletal structures to the plasma membrane 
i Causes the chemical reactions that remove phosphates from a number of different molecules 
j Cell derived leukocyte that is part of the immune system to fight against infectious diseases and foreign material 
k Controls a spectrum of diverse cellular processes 
l Ca2+ dependent phospholipid binding proteins with potential anti-inflammatory activity 
m Filament protein 
n Involved in oxygen transport from the lung to the various peripheral tissues 
 
Table 3-1 cont’d. 
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Table 3-2. Proteins identified at single peptide level using BLAST. De novo sequenced peptides obtained from a gel 
digest were searched using BLAST and proteins were matched based on sequence similarity and evolutionary relationship 
using the NCBI database. The top E-values with the closest related organisms are reported. 
 
 Band  
Number 
m/z Charge De novo Sequence Protein Function Accession Number Protein 
Length 
Organism E-Value 
           



























 B4 701.3 +2 YQINQQWER Fibronectin a
 
Q91740 2481 Xenopus laevis 0.013 
 
 B1 613.9 +2 LIALLEVLSQK Filamin-C b
 
Q14315 2725 Homo sapiens 0.019 
 














 B2 736.4 +2 AQQVSQGLDLLTAK Vinculin 
 
c P12003 1135 Gallus gallus 5e-05 
 






































 B2 628.7 +2  
LITKAVSASK 
 































          
                                                            
a Cell adhesion, cell motility, opsonization, wound healing & cell shape maintenance 
b Plays a central role in muscle cells, probably by functioning as a large actin-cross-linking protein 
c Involved in attachment of the actin-based microfilaments to the plasma membrane; may also play roles in cell morphology & locomotion 
d Plays a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability; a mixture of histones H2B and H4 has antimicrobial activity against Gram-positive bacterium 
M.luteus 
e Condensation of nucleosome chains into higher order structures 
f Used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses 
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B6 751.4 +2 VFGGGTKLTVL QPK Ig Λ chain V-III region 
LOI 































































 B5 506.2 +3 QEYDESGPSIVHR γ-Actin k
 
Q5JAK2 375 Rana lessonae  3e-05 
 













































































































          
                                                            
g Activates the alternative complement pathway by binding to the short consensus repeat domain 3 (SCR3) of factor H 
h Involved in oxygen transport from the lung to the various peripheral tissues 
i Cross-linking actin to other cytoskeletal proteins 
j Anchor actin to a variety of intracellular structures 
k Highly conserved protein involved in various types of cell motility 
l Enhances the activity of immunoagents 
m Displace diazepam from the benzodiazepine recognition site located on the GABA type A receptor. Diazepam binding inhibitor (32-86) has antibacterial properties 
n Cell derived leukocyte that is part of the immune system to fight against infectious diseases and foreign material 
o Lysosomal degradation of sphingolipids takes place by the sequential action of specific hydrolases 
p Required for neuronal cell differentiation 
q Cytoskeletal protein in lymphocyte involved in connections of major cytoskeletal structures to the plasma membrane 
Table 3-2 cont’d. 
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B2 525.8 +2 LGTFLEN Histone acetyltransferase 
p300 
r Q09472 2414 Homo sapiens  36 
 
 B4 821.9 +2 V+QQQADDAEER Putative tropomyosin α-3 
chain-like protein 





























































 B1 831.4 +2 NSWGTSWGEDGYFR Dipeptidyl-peptidase 1 
(Cathepsin C) 
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r Functions as histone acetyltransferase and regulates transcription via chromatin remodeling 
s Binds to actin filaments in muscle and non-muscle cells 
t Involved in the organization of the cytomatrix at the nerve terminals active zone (CAZ) which regulates neurotransmitter release 
u Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans 
v The surface protein gp120 (SU) attaches the virus to the host lymphoid cell by binding to the primary receptor CD4 
w Plays a role in the generation of cytotoxic lymphocyte effector function; the central coordinator for activation of many serine proteases in immune/inflammatory cells 
x Component of the origin recognition complex (ORC) that binds origins of replication 
y Receptor that may have an important role in cell/cell signaling during nervous system formation 
z Plays a central role in the complement system and contributes to innate immunity 
aa Actin-binding protein; plays a role in the activation of T-cells 
Table 3-2 cont’d. 
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Peptide sequences found using BLAST was used in a search of both the SwissProt and NCBI 
databases. Of the peptides found by de novo sequencing, 81% matched similar proteins in the 
two databases. The proteins were identified at single peptide level by observing the E-value, 
which is a statistical value indicating sequence similarity and potential evolutionary 
relationship.243 A low E-value indicates a statistically significant match. The peptides listed in 
Table 3-2 are those returned from the BLAST search having the lowest three E-values (the 
complete Table can be found in Appendix A). Notably, the organisms associated with the low E-
value peptides are close in homology to alligators, for example Chelonia caretta (turtle), Caiman 
crocodilus (caiman) and Gallus gallus (chicken). Eleven of the thirty-two de novo sequences had 
chicken protein sequences in the top three hits. Also, there were several identified proteins that 
are associated with leukocytes and the immune system. However, the identification of 
hemoglobin β suggests contamination from red blood cells during isolation of the leukocytes 
from the whole blood. Other peptides in the table matched proteins that have not, to date, been 
associated with the immune system. 
To assess the quality of the protein matches, several factors were considered. First, the 
number of peptides matching the protein was considered. For example, three of the de novo 
sequences in Table 3-2 matched the protein fibrinonectin, which increases the confidence level 
that a similar protein is present in the alligator leukocyte. The percentage of matching residues 
was also considered. The de novo sequenced peptides matching fibrinonectin had 100% 
sequence alignment with that protein. However, the sequence coverage was only 3%.  
Last, a BLAST search was performed using a limited taxonomy containing birds and 
reptiles. Limiting the taxonomy search reduced the random matches and resulted in lower E-
values for the protein matches compared to the full database search. This data is shown in the 
supplementary material (Appendix A, Table 2). 
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The proteins were grouped based on their functionality. Protein functions were divided 
into six groups: other, cytoskeletal proteins, immune proteins, enzymes, DNA/synthesis proteins, 
and unknown. Proteins involved in the cytoskeletal system, immune system, and other make up 
the three most abundant groups of peptides with approximately 37%, 23% and 23% respectively.   
De novo sequencing coupled with Mascot and BLAST searches aided in the identification 
of 43 proteins that are similar to the proteins isolated from the alligator’s leukocyte extract. To 
identify and characterize the function of the proteins derived from the de novo sequenced 
peptides, two approaches were employed. First, if a protein was identified from more than one de 
novo sequenced peptide in the same gel band, the protein and its function were assigned. Second, 
de novo sequenced peptides with only one peptide matching a protein, the phylum of the 
matched protein was considered. From the three highest E-values from the BLAST search, seen 
in Table 3-2 (for the complete table, refer to Appendix A), E-values less than one were first 
considered and the organisms associated with the protein hit were classified by biological 
phylum and only animals were considered. Matched proteins that are from closely related 
species, e.g. reptiles and birds, were moved to the top of the list. Of the de novo sequenced 
proteins, 29% matched invertebrates 39% mammals, 18% birds, 6% amphibians, 5% fish and 3% 
reptiles. Although proteins from invertebrates are highly represented, it should be noted that 81% 
of the database proteins are associated with invertebrates. The taxonomic distribution of 
vertebrate proteins in the Swiss-Prot database is 50% mammal, 25% fish, 10% bird, 9% 
amphibian, and 6% reptile.244 This can be compared to 55% mammal, 27% bird, 8% amphibian 
6% fish, and 4% reptile, thus bird proteins are overrepresented in the matched proteins and fish 
proteins are underrepresented. This is consistent with evolutionary reports that birds have a close 
phylogenetic relationship to crocodilians.245 
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A putative function was assigned to the de novo sequenced proteins identified based on 
the function of the matched proteins. The majority of the proteins identified in the alligator 
leukocyte are common to proteins identified in leukocytes of other class of animals. 
 A range of proteins related to the immune system were identified. The identified 
immune system proteins were fibrinonectin, histone H4, Ig kappa chainV-1 region, Ig lambda 
chain V-III region, lysozyme C, acyl-CoA-binding protein, myeloid protein, cathepsin C, 
complement component c3, ubiquitin, and polyubiquitin. The protein ubiquitin was identified 
with 32% sequence coverage, the largest observed. This is consistent with previous reports 
demonstrating that ubiquitin is a highly conserved protein in eukaryotes.246  Ubiquitin has several 
functions such as the removal of damaged or unnecessary proteins and controlling other cellular 
processes such as antigen processing, apoptosis, immune response and inflammation.247 
Although it has several functions, it is related to the immune system. A de novo sequenced 
protein matched lysozyme (Chelonia mydas) from residue 50 to 61. Lysozyme was one of the 
first antibacterial proteins isolated from insects and is also a component of the humans innate 
immune system.248 The complement C3 protein also plays a role in innate immunity in 
organisms248, 249 and plays a major role in the activation of the complement system, which helps 
to remove pathogens.249 A de novo sequenced protein matched histone (Gallus gallus), a class of 
proteins that are involved in DNA packaging; however, they have been reported to behave as 
antimicrobial agents.250  
 Several cytoskeletal proteins, myosin alkali light chain, myosin regulatory light chain, β-
actin, actin-2, actin-1, annexin V, annexin I, ras-related protein O-krev, vimentin-4, talin 1, 
filamin-C, vinculin, microtubule-actin cross-linking factor 1, α-actinin-1, actin, plastin-2, and 
putative tropomyosin γ-3 chain-like protein were identified. These were the major group of 
proteins identified and play an important role in the function of leukocytes. Actin is the most 
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abundant protein in all eukaryotic cells251 and is responsible for muscle contraction and cell 
motility and works in conjunction with myosin protein through actin-myosin interactions.251, 252 
Examples of cell movements include invasion of tissue by white blood cells to fight infection 
and migration of cells involved in wound healing.252 Actin has multiple functions but is also 
related to the immune system; it regulates the integrin function, which is important for 
inflammation and immunity. Other identified cytoskeletal proteins, talin, α-actinin, plastin-2, and 
filamin-C, also play a role in the actin cytoskeletal system.253-256 Variations of myosin and 
tropomyosin proteins work along with actin to assist in phagocytosis of microorganisms.257 
Annexins have various functions such as regulation of membrane organization and of Ca2+ 
concentrations within cells as well as participation in phagocytosis.258 Vinculin, another 
cytoskeleton protein, is necessary for cell movement and changes in cell shape.259 Vimentin, a 
filament protein, is involved in structural processes such as wound healing and is also found to 
be secreted by macrophages.260 Also identified in this study was a ras-related protein; these 
proteins are GTPases that are a part of the Ras superfamily of proteins and are involved in 
regulating cell behavior such as cell growth and action.261 
A class of enzymes known as endonucleases was also identified with high Mowse scores. 
These enzymes are commonly found in bacteria and behave like an immune system:  bacteria use 
these enzymes to cut DNA from foreign material destroying them.262 Although endonucleases 
are typically found in bacteria, alligator leukocyte may contain proteins that are similar to 
endonuclease protein and play a similar role. Alkaline phosphatase is a key enzyme involved in 
the process of dephosphorylation. It is also found to be involved in the protection against 
endotoxins, which may be lethal after an infection.263 
Three matched proteins are hypothetical proteins from the western clawed frog, (Xenopus 
tropicalis), house mouse (Mus musculus), and chimpanzee (Pan troglodytes). The Pan 
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troglodyte’s hypothetical protein had four matching peptide sequences suggesting that a similar 
protein is expressed in the alligator leukocyte. However, the function of these hypothetical 
proteins is not known and their relationship to the immune system cannot be determined.  
There were proteins identified from the Mascot search that had a score greater than 57 but only 
one matching peptide:  lysozyme C and ras-related protein O-krev (Table 3-2). These proteins 
cannot be identified with the same degree of confidence as the other proteins that had more than 
one peptide matching the protein. The proteins characterized as other have not been previously 
identified in leukocytes of other organisms. However, the E-values are high which suggests 
limited sequence identity and evolutionary relationship. 
3.4 Summary 
In the work described in this Chapter, proteins from the leukocytes of the American 
alligator (Alligator mississippiensis) were identified and their functions were characterized by 
adopting a general proteomics approach. A three-step strategy was performed to identify similar 
proteins in the gel bands and spots: de novo sequencing, Mascot search, and BLAST search. 
Mascot search results identified eighteen proteins with sequence similarity to the alligator 
leukocyte proteins. The identified proteins are common among eukaryotes and are associated 
with the immune system. The BLAST search results showed that 81% of de novo sequenced 
proteins matched similar proteins in the database. Among the identified proteins, the majority 
were related to the cytoskeletal system. 
The BLAST search identified proteins most closely related to vertebrates. Proteins 
originating from birds, particularly chicken, were overrepresented in the matched proteins and 
correlated with immune related proteins reported for other species. Fish species was the least 
represented species among the matched proteins.  
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CHAPTER 4. SMALL MOLECULE INTERFERENCES IN ALLIGATOR 
MISSISSIPPIENSES LEUKOCYTE EXTRACT 
 
 In this chapter, experiments in which small molecule interferants in the leukocyte extracts 
from Alligator mississippiensis were separated and purified using reversed phase liquid 
chromatography are described. Seven bacterial species including Escherichia coli, Enterobacter 
cloacae, Shigella flexneri, Klebsiella oxytoca, Salmonella, Staphylococcus aureus, and 
Staphylococcus epidermidis were assessed for antimicrobial activity. The active fractions were 
characterized using tandem mass spectrometry and X-ray crystallography. The results from the 
mass analysis and X-ray crystallography suggest that the component exhibiting antimicrobial 
activity was ethylenediaminetetraacetate (EDTA), the anticoagulant agent used during the 
collection of the alligator blood. Tandem mass spectrometry data along with accurate mass 
measurements suggests that the other small molecule interferant is spermine. 
4.1 Introduction 
 Antimicrobial drug resistance is a growing problem. Numerous bacteria such as 
Staphylococcus aureus, Salmonella, E. coli, Pseudomonas aeruginosa, and Streptococcus 
pneumoniae have developed resistance to antibiotics.264 One of the most resistant bacteria 
affecting hospital settings is Staphylococcus aureus: over 50% of its bacterial strains have 
become resistant to penicillin.264, 265 Due to this problem, new antibiotics with broad spectra of 
activity must be developed. 
Studies have shown that when extracts of alligator leukocytes from blood are exposed to 
bacterial pathogens, the growth of the bacteria is inhibited.266 Several anticoagulant agents that 
prevent blood clotting are available, such as EDTA, heparin, citrate, and oxalate. EDTA is a 
chelating agent that synergistically inhibits growth of bacteria with antimicrobial agents267 such 
as sulfamethoxazole, trimethoprim,268  penicillin G, ampicillin, tetracycline, and 
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chloramphenicol.269 Studies have shown that EDTA can also inhibit bacterial growth 
independently.270 EDTA enhances the effectiveness of antibiotics against bacteria, particularly 
gram-negative bacteria, and chelates Ca+2 and Mg+2 which disrupts the bridge between them and 
lipopolysaccharide (LPS) in the bacterial outer membrane.267, 271 
Peptides and small molecules have the potential for therapeutic use. Small molecules are 
less costly and easy to synthesize and are stable, therefore longer half-life.272 However, small 
molecules can potentially interact with multiple targets and accumulate in tissues causing 
toxicity.272 Unlike small molecules, peptides are more specific and can be chemically modified 
to make the peptide less susceptible to proteolysis in vivo.272  
Another small molecule that exhibits antimicrobial activity is spermine. Spermine is a 
biological polyamine that is found to be widely distributed in animal tissues.273 It has 
antibacterial activity, providing resistance to a wide range of microorganisms such as S. aureus, 
S. albus, and B. anthracis.273, 274 Spermine was first isolated from semen and exhibits 
antimicrobial activity against gram-positive microorganisms.275  
In this chapter, we report that EDTA and spermine are present and isolated from 
leukocyte extracts of alligators. These molecules can potentially cause interferences with the 
activity measurements.  
4.2 Experimental 
 Leukocyte extracts were obtained from the blood of alligators as described in Section 2.1. 
In this study, which was the first studies performed on isolation of peptides from alligator 
leukocytes, 0.1 mM EDTA was used as the blood anticoagulant.  
 A Bradford protein assay was used to determine the concentration of proteins in the 
alligator leukocyte extracts. A 2 mg/mL quantity of bovine serum albumin (BSA) was used to 
prepare five BSA dilutions from 125 to 2000 µg/mL. A 0.1% acetic acid buffer was used to 
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perform the dilutions. Each standard and leukocyte protein extract was pipette into clean test 
tubes and mixed with the protein dye reagent. The protein samples were assayed in triplicate and 
incubated for 5 min before UV-Vis analysis. Absorbance was measured at 595 nm for both the 
protein standard and leukocyte protein extracts. The concentration of the leukocyte protein 
mixture was determined using a standard Bradford curve.276  
 The leukocyte extract was tested for antimicrobial activity before chromatographic 
separation. A radial diffusion assay was used to monitor bacterial growth inhibition.277 
Leukocyte extracts and chromatographic fractions of the leukocyte extracts were pipetted into 
wells on the activity plate, incubated overnight at 37ºC, and zones of bacterial growth inhibition 
were measured the following day. 
Alligator leukocyte extracts were separated by reverse phase liquid chromatography (RP-
LC) and peak fractions were monitored with a photodiode array (PDA) detector and manually 
collected in 2 minute intervals. For PDA detection, the UV spectrum was recorded between 190 
and 400 nm.	 The fractions were tested for antimicrobial activity and the active fractions were 
lyophilized and re-suspended in 0.01% (v/v) aqueous acetic acid. The fractions that exhibited 
antimicrobial activity were injected onto the C18 reversed phase (RP) column using a gradient of 
10–90% acetonitrile over 40 minutes for further purification and analyzed using ESI-TOF mass 
spectrometry. 	
	 The purified fraction that exhibited antimicrobial activity was submitted for structural 
characterization using X-ray crystallography. Tandem mass spectrometry (MS/MS) using the 









































































-2. (A) Purification of Fractions 2 an
69 






4.3.2 Antimicrobial Activity 
 Results from this study showed that Fractions 2 and 3 exhibited antimicrobial activity 
against Escherichia coli, Shigella flexneri, Salmonella, Staphylococcus aureus, and 
Staphylococcus epidermidis (Table 4-1). When tested against Klebsiella oxytoca, a gram-
negative bacterium, neither of the fractions exhibited activity. However, growth inhibition was 
observed for Fraction 2 against Enterobacter cloacae, a gram-negative bacterium, but not for 
Fraction 3. The largest antimicrobial activities from Fractions 2 and 3 were observed for 
Staphylococcus epidermidis, a gram-positive bacterium; zones of inhibition were 17 and 14 mm 
respectively. The lowest activity was observed in Salmonella, a gram-negative bacterium, at 5 
and 4 mm respectively.  
	
Table 4-1. Antibacterial activity of Fractions 2 and 3 from leukocyte extract against bacterial 
species tested using radial diffusion assay. 
	
Bacterial Strain 
Zone of Inhibition (mm) 
(F2) 
Zone of Inhibition (mm) 
(F3) 
Escherichia coli 10.0 5.0 
Enterobacter cloacae 7.0 0 
Shigella flexneri 6.0 5.0 
Klebsiella oxytoca 0 0 
Salmonella 5.0 4.0 
Staphylococcus aureus 15.0 10.0 
Staphylococcus epidermidis 17.0 14.0 
 
Both fractions exhibited antimicrobial activity towards both gram-negative and gram-positive 
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 In the work described in this Chapter, leukocyte extracts were subjected to purification 
and characterization by LC ESI-MS, MS/MS and X-ray crystallography analysis. The results 
from this study suggest that EDTA, a blood anticoagulant, in the presence of a protein might 
contribute to inhibition of bacterial growth. In addition, previous studies have shown that EDTA 
contributes to bacterial growth inhibition at both high and low concentrations.270  An alternate 
explanation is that the antimicrobial activity resulted from a molecule that was not detected in 
the mass spectrometry analysis. RP separation was capable of reducing the complexity of the 
leukocyte protein mixture; however, the chromatographic fractions were still not sufficiently 
pure to identify the specific molecules that contributed to antimicrobial activity. Additional off-
line RP separations assisted in small molecule purification and antimicrobial activity was 
identified for fractions collected within the first six minutes. The masses of the small molecules 
detected in the active fractions were measured by ESI-MS and the small molecules were 
identified by empirical formula calculations based on accurate mass measurement. A molecule, 
from the active fractions, F2 and F3 at m/z 203.2 had the formula, C10H26N4 with 6 ppm mass 
error. In addition, tandem MS analysis revealed fragmentation patterns for this ion that matched 
the molecule spermine. Another molecule from fraction F2 at m/z 315.1 (3 ppm accuracy) had 
the formula C10H16N2O8Na and X-ray crystallography was used for further characterization 
where results from the structural database identified the structure from the active fraction as 
EDTA disodium salt.  
 The results from this study suggest that EDTA may not be a suitable anticoagulant agent 
for isolation of blood proteins when testing for antimicrobial activity. As a result, for future 
studies the anticoagulant agent heparin was used as a substitute. The other small molecule that 
was identified was spermine, which is typically found in all animal cells and is usually excreted 
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from semen and pancreatic tissue. Blood contains various proteins that are secreted or shed from 
cells and tissues throughout the body.78 Therefore, it may not be possible to eliminate spermine 
as an interferant, hence for the studies described in the following chapters, small molecules 
eluting within the first six minutes from the leukocyte extracts were not considered as potential 




CHAPTER 5. ISOLATION AND DE NOVO SEQUENCING OF ANTIMICROBIAL 
PEPTIDES FROM LEUKOCYTES OF THE AMERICAN ALLIGATOR (ALLIGATOR 
MISSISSIPPIENSIS) 
 
The goal of the research in this chapter was to isolate novel peptides with antimicrobial 
activity from American alligator blood (Alligator mississippiensis). Reversed-phase high 
performance liquid chromatography (RP-HPLC) was used to separate and purify peptides from 
leukocyte extracts and the HPLC fractions were checked for activity. A partially purified fraction 
containing two major peptides at 4.7 and 4.9 kDa was tested for antimicrobial activity against E. 
coli, E. cloacae, and K. oxytoca. The peptides were analyzed using ion mobility spectrometry 
mass spectrometry. Matrix assisted laser desorption ionization time-of-flight/time-of-flight mass 
spectrometry (MALDI-TOF/TOF) was used to generate MS/MS data for the peptides and de 
novo sequencing was used to determine their sequence. The 4.7 kDa peptide was aligned to other 
antimicrobial peptides and showed 36% sequence identity with Pilosulin 4 and the 4.9 kDa 
peptide showed 33% sequence identity to SpStrongylocin 2. 
5.1 Introduction 
Increasing bacterial resistance to antibiotics has become the driving force behind the 
development of new anti-infectives to replace or supplement conventional antibiotics.279 
Antimicrobial proteins and peptides from natural sources show promise as new antibiotics. 
Antimicrobial peptides (AMP) are important components of the innate immune system that have 
been isolated in plants,280 vertebrates,281 and invertebrates282 and have potential for 
pharmaceutical use. Most antimicrobial peptides are small (<10 kDa), cationic, lysine and 
arginine containing molecules; however, some anionic peptides have also been reported.25 
Cationic proteins and peptides have an affinity for microbe cell surfaces, which have negatively 
charged groups. This attraction is dependent on electrostatic interactions and their tertiary 
79 
 
structure.283 Cationic proteins and peptides vary in their size, structure, and mechanism of 
action.283 
In some vertebrates such as mammals and reptiles, antimicrobial proteins and peptides 
are found in the blood, particularly in the neutrophils. There are several classes of antimicrobial 
proteins and peptides associated with neutrophils, such as lactoferrin, cathelicidins, calprotectin 
and defensins.283 Defensins are small cationic peptides around 4 kDa with a broad antimicrobial 
activity against bacteria, fungi, viruses, and parasites.284 β-defensins serve as effector molecules 
of innate immunity, providing an initial defense against infectious agents,285 and have been 
identified in bovine neutrophils,286 turtle33 and avian leukocytes,287 and human plasma.288 
Leukocytes in the blood of crocodilian species have a range of antimicrobial, antifungal, and 
antiviral activity,1, 289, 290 but little is known about antimicrobial peptides in Alligator 
mississippiensis.  
There is limited information about reptile antimicrobial peptides. To date there are very 
few reptilian antimicrobial peptide sequences identified among the nearly 400 that have been 
reported from other sources.33, 36 The Alligator mississippiensis leukocytes have a broad range of 
activity towards bacteria, viruses and fungi.1 Some studies have been performed to characterize 
the proteins and peptides from alligator leukocytes;291 however, none have been sequenced. 
De Novo sequencing is a common approach for mass spectrometry based sequencing of 
peptides and proteins that are not in a protein sequence database. De Novo sequencing entails 
identifying peptide sequences without any previous knowledge of the protein sequence.164  
In this study, we isolated two novel peptides that exhibit antimicrobial activity from the 
leukocytes of the American alligator (Alligator mississippiensis) using reversed-phase 
chromatography separation. The peptides were sequenced using de novo sequencing and 
compared to other known antimicrobial peptides. 
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5.2 Experimental  
5.2.1 Isolation and Extraction of Antimicrobial Peptides  
Blood was drawn from farm and wild alligators ranging in size from 5 to 12 feet for 
isolation of leukocytes using an approach described in Section 2.1.  
5.2.2 Microbial Strains 
All bacterial strains were obtained from American Type Culture Collection (ATCC). The 
following bacterial strains were used: Escherichia coli (ATCC 43827), Enterobacter cloacae 
(ATCC 23355), and Klebsiella oxytoca (ATCC 33496).  
5.2.3 Antimicrobial Activity  
The antimicrobial activity of the leukocyte extracts and the peptide fractions from HPLC 
eluents were determined using an antimicrobial assay.278 Trypticase soy broth containing 1% 
agarose was sterilized and 15 mL aliquots were transferred to centrifuge tubes. The nutrient 
broth was inoculated with 20 µL of a log phase culture of bacteria and added to petri dishes. 
Wells were cut into the petri dish using a sterilized pipette with a vacuum line attached for 
suction. Five microliters of leukocyte extract dissolved in aqueous 0.1% acetic acid (v/v) was 
added to each well and allowed to diffuse at room temperature for 3 hours. The plates were then 
incubated at 37oC overnight and the zones of bacterial growth inhibition were measured. The 
antibiotic polymyxin B at 2 × 10-5 M was used as a positive control and aqueous 0.1% acetic acid 
(v/v) was used a negative control.   
5.2.4 Peptide Separation 
Leukocyte extract in 0.1% acetic acid was centrifuged to remove any insoluble residue. A 
10 µL volume of concentrated sample was injected with an autosampler system onto a 0.3 × 1 
mm trapping column on a LC system (Agilent) at a flow rate of 0.3 ml/min. The sample was 
eluted onto a 2.1 × 30 mm, 3.5 µm particle size C18 column (Zorbax) and separated using a 
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gradient of 5 to 60% B (80% acetonitrile (v/v) and 20% water (v/v) containing 0.1% formic acid 
(v/v)) over 70 min with a flow rate of 0.3 mL/min. The eluent was monitored by UV absorbance 
from 190 to 480 nm. A fraction collector was used to collect the eluent at timed intervals for 
further characterization and activity studies. 
5.2.5 Ion Mobility Mass Spectrometry 
The peptide samples were diluted in 0.1% formic acid and injected on the nanoAcquity 
ultra pressure liquid chromatography (UPLC) system at a flow rate of 500 nL/min. The peptides 
were separated using a gradient of 3–40% B over 30 minutes. The peptides were ionized using a 
nano-electrospray source, operated in positive ion mode and analyzed via a quadrupole mass 
analyzer before being introduced to the ion mobility spectrometry (IMS) on the ESI-Q/IMS/TOF 
MS. The quadrupole was operated in RF mode in order to record full mobility spectra and the 
data was processed using MassLynx software. A pressure of 0.5 bar of nitrogen was maintained 
in the ion mobility (IM) cell.  
5.2.6 MALDI Mass Spectrometry 
Alligator leukocyte fractions were mixed on a stainless steel plate using a 1:1 ratio of 1 
µL sample and 1 µL saturated matrix including α-cyao-4-hydroxycinnamic acid (CCA) and 2-
hydroxy-5-methoxybenzoic acid (sDHB) matrix solution containing 0.1% v/v TFA for molecular 
mass determination. The sample and matrix solution was air-dried at room temperature and 
analyzed in TOF mode on the MALDI TOF/TOF MS. Mass spectra were recorded in reflector 
positive ion mode with external calibration using a standard calibration mixture. Spectra were 
500 shot averages collected using a mass range from 420–5000 Da. Masses were determined 
using FlexAnalysis software. MS/MS data was obtained by LIFT/CID fragmentation. MS/MS 
experiments were carried out in reflectron mode and more than 5000 laser shots were collected.  
The MS/MS data were processed in FlexAnalysis. 
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5.2.7 ESI Mass Spectrometry 
 The fraction containing the two peptides of interest was also analyzed on the ESI-QTOF. 
The peptide sample was diluted twofold with 50% ACN solution containing 0.1% FA (v/v). 
MS/MS experiments were performed on the selected parent ion and the collision energies were 
varied from 25 to 60 eV in 5 eV intervals. 
5.2.8 De Novo Sequencing and Sequence Analysis 
De Novo sequencing of the peptide fragments generated using MALDI MS/MS was 
performed with BioTools. The de novo sequencing results were verified manually. The peptide 
sequences produced by de novo sequencing were aligned with β-defensins peptide sequences 
from other vertebrates for sequence comparison.  
The alligator antimicrobial peptide sequence was compared to other antimicrobial 
peptides in the Antimicrobial Peptide Database.292 The alligator antimicrobial peptide was also 
aligned to find the most similar peptides in the database.   
5.3 Results and Discussion 
5.3.1 Antimicrobial Activity of Leukocyte Extracts 
The antimicrobial activity of the alligator leukocyte extracts was tested against three 
species of bacteria. The leukocyte extracts exhibited antimicrobial activity against gram negative 
bacterium E.coli, K. oxytoca, and E.cloacae with approximately 0.5 mm zone of inhibition.  
5.3.2 Peptide Purification  
Several RP separations were run to separate and collect the active peptides. The 
separation of the peptide and protein mixture from the alligator leukocytes produced more than 
12 fractions (Figure 5-1). The fraction collected at 15 min at 20% acetonitrile showed 
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36 E 379.1282 4497.3138 4 
37 C 250.0856 4600.3230 3 
38 G 147.0764 4657.3445 2 
39 A 90.0550 4728.3816 1 
Mass tolerance: 0.5 Da 
MS/MS tolerance: 0.5 Da 
Bold represents ions found in the mass spectrum. 
 
Peptides in the low mass range of the spectrum were absent due to inefficient fragmentation of 
the 4.7 kDa peptide. However, the fragments in the higher m/z range correlated with the “b” and 
“y” ions in the mass spectrum, and allowing the determination of the peptide sequence from the 
C- to N-terminus. 
The 4.9 kDa peptide was sequenced in a similar manner to the 4.7 kDa peptide and the 
sequence obtained for this peptide is 
 MGAKTKWKRFRGLDTCVFFLLSCKKHCCLLHHTKGRNKTKAAV.  
The peptide primary structure was determined based on the fragment ions in Table 5-2. 
Fragments in the mass spectrum that were not present in either the b- or y-ion series for the 4.9 
kDa peptide were predicted by the de novo software. 	
 
Table 5-2. Fragment ions predicted and confirmed in the mass spectrum for the 4.9 kDa peptide. 
N-term Residue y-series b-series C-term 
1 M 4961.6449 132.0478 43 
2 G 4830.6044 189.0692 42 
3 A 4773.5829 260.1063 41 
4 K 4702.5458 388.2013 40 
5 T 4574.4509 489.2490 39 
6 K 4473.4032 617.3439 38 
7 W 4345.3082 803.4233 37 
8 K 4159.2289 931.5182 36 
9 R 4031.1339 1087.6193 35 
10 F 3875.0328 1234.6877 34 
11 R 3727.9644 1390.7889 33 
12 G 3571.8633 1447.8103 32 
13 L 3514.8418 1560.8944 31 
14 D 3401.7578 1675.9213 30 
15 T 3286.7308 1776.9690 29 
16 C 3185.6832 1879.9782 28 
17 V 3082.6740 1979.0466 27 
18 F 2983.6056 2126.1150 26 
19 F 2836.5371 2273.1834 25 
20 L 2689.4387 2386.2675 24 
21 L 2576.3847 2499.3516 23 
22 S 2463.3006 2586.3836 22 
23 C 2376.2686 2689.3928 21 
24 K 2273.2594 2817.4877 20 
25 K 2145.1644 2945.5827 19 
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Incomplete sequence information was determined from the spectrum due to the lack of 
fragmentation of the parent ion. Fragmentation with lower collision energies (e.g. 25 eV) and 
higher collision energy (e.g. 60 eV) were the same. This data suggests that 1) the size of the 
intact peptide is too large to fragment using low energy CID and 2) disulfide bond(s) may be 
present which will stabilize the peptide structure and make it difficult to fragment.  
5.3.6 Alligator Peptide Sequence Analysis 
 The alligator peptide sequence generated from  the 4.7 kDa peptide was searched against 
the antimicrobial peptide database for sequence similarity and it showed 36% sequence similarity 
to Pilosulin 4, an antimicrobial peptide from an Australian ant and 33% sequence homology to 
NA-CATH, a snake cathelicidins. The similarities between the antimicrobial peptides are seen in 









Figure 5-7. Sequence comparison among antimicrobial peptides with alligator 4.7 kDa peptide. 
Residues highlighted in blue represent identity in the sequence. 
 
 
The alligator peptide sequence has low sequence homology when compared to antimicrobial 
peptides from other species, including snakes, from the antimicrobial peptide database. This 
suggests that the alligator sequence may function as an antimicrobial peptide based on its 
antimicrobial characteristics but its sequence does not share strong homology to other reptilian 
antimicrobial peptides.   
Ant Peptide Alignment 
-Alignment Result-: P D + I T + K L N I K K L T K + + + A T C + K V I S K G A S M C K V L F D K + K K + Q 
E + + +  
--Input Sequence--: R D H R T K K L + + K K F D K S M M P E C E K + + C K + E S + + K + D F K K N K K T W 
E C G A 
Snake Peptide Alignment 
-Alignment Result-: + + K R F K K F F K K + L K N S + + + + + V K + K R A K K F F K K P K V I G V T F P F 
--Input Sequence--: R D H R T K K + L K K F D K + S M M P E C E K C K + E S K D F K K N K + K T W E C G A 
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The 4.7 kDa peptide has a theoretical isoelectric point (pI) of 9.63 which is close to the 
average pI of antimicrobial peptides which is 9.26.293 However, a high positive net charge is also 
required for antimicrobial peptides to carry out their function.  The 4.7 kDa peptide sequence has 
a net charge of +8 at pH 5.5, indicating that it will also be cationic under in vivo conditions near 
physiological pH. The cationic nature of antimicrobial peptides is conserved and it may be 
essential for the initial electrostatic attraction to the phospholipid membrane of bacteria and 
fungi.24  
There are seven hydrophobic residues at positions 8, 11, 15, 16, 28, 35, and 39 and the 
peptide may form an alpha helix. The total net charge, hydrophobic ratio, and Boman index for 
the peptides were calculated using the antimicrobial peptide prediction server. The antimicrobial 
peptide prediction server predicts whether a new peptide sequence has the potential to be 
antimicrobial based on principles such as size, net charge, hydrophobic percentage and residue 
composition. The system can also perform simple structural predictions, for example if 
hydrophobic residues occur at every two to three residues in the peptide sequence an 
amphipathic helix will be predicted.292 
The Boman index is an estimate of the antimicrobial peptide’s potential to bind to other 
proteins.294 A lower index value (≤1) indicates that the peptide will most likely have more 
antibacterial activity with little side effects in vivo whereas a higher index value indicates that the 
peptide is multifunctional.294  The sequence determined for the peptide measured at 4.7 kDa has 
a Boman index of 3.8 kcal/mol. It also has an even number of cysteines which suggests that it 
may form a disulfide-bond linked beta structure,292 similar to defensins. The percent 
hydrophobicity of this peptide is 25%, which is similar to that for defensins;295 suggesting that 
the peptide may have antimicrobial activity.296  
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The sequence similarity search for the 4.9 kDa peptide showed 33% sequence identity to 
SpStrongylocin 2 from sea urchin and Brevinin-2PTa from frog. The sequences of the peptides 










Figure 5-8. Sequence similarity between antimicrobial peptides with alligator 4.9 kDa peptide. 
Highlighted in blue represent identical peptides.  
 
Like the 4.7 kDa peptide, the sequence similarity with the alligator 4.9 kDa peptide to other 
peptides in the database is low.  
 The 4.9 kDa peptide sequence has a net charge of +13 at pH 5.5 and a theortical pI of 
10.26. The peptide has 19 hydrophobic residues, 2 Val, 5 Leu, 3 Phe, 4 Cys, 1 Met, 3 Ala, and 1 
Trp and the percent hydrophobicity of the peptide is 44%. The peptide sequence of the 4.9 kDa 
peptide contains an even number of cysteines; therefore it may form a disulfide-bond linked beta 
structure similar to β-defensins. The Boman index for this peptide is 1.68 kcal/mol, which is 
similar to defensins,295 suggesting that the peptide may have antimicrobial activity.294  
5.4 Summary 
 Peptides and proteins were extracted from alligator leukocyte and the mixture was tested 
for antimicrobial activity. The extract was separated, each fraction tested for antimicrobial 
activity, and the peptides from the active fraction were sequenced using mass spectrometry and 
de novo sequencing. Based on ESI and MALDI MS measurements, the masses of the 
predominant peptides in the active fraction were found to be 4.7 and 4.9 kDa. The peptides were 
Sea urchin Peptide Alignment 
-Alignment Result-: W N P F R K L Y R K E C N D V T S C D T V S G V K T C T K K N C C + + + H R 
K F F G K T I L K A P E C T V I S  
--Input Sequence--: M G A K T K W K R F R G L D + T + C + + V F F L L S C + K K H C C L L H H T 
K G R N K T + + K A + + + A V + + 
 
Frog Peptide Alignment 
-Alignment Result-: + G A I K D A L K + + + G A A K T + V A V E L L + + K K A Q C + + + + + K + 
L E K T + + + C  
--Input Sequence--: M G A + K T K W K R F R G + L D T C V + F F L L S C K K H C C L L H H T K G 
R N K T K A A V 
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not separated by RP-HPLC; hence ion-mobility mass spectrometry was used to separate the 
peptides by their size, mass, and charge for MS analysis and sequencing. Due to limited 
fragmentation from IM-MS, MALDI MS/MS was used with de novo sequencing to determine 
the sequence of the 4.7 kDa peptide. The putative sequence has 39 residues and a net charge of 
+8 at pH 5.5 and the 4.9 kDa peptide has a putative sequence containing 43 residues and a net 
charge of +13 at pH 5.5. Based on the peptide’s primary structures, size, cationicity, and its 
predicted antimicrobial activity; the 4.7 and 4.9 kDa peptide properties are consistent with the 




CHAPTER 6. ISOLATION AND DETERMINATION OF THE PRIMARY STRUCTURE 
OF A LECTIN PROTEIN FROM THE SERUM OF THE AMERICAN ALLIGATOR 
(ALLIGATOR MISSISSIPPIENSIS)* 
 
In this chapter mass spectrometry in conjunction with de novo sequencing for 
determining the amino acid sequence of a 35 kDa lectin protein isolated from the serum of the 
American alligator (Alligator mississippiensis) that exhibits calcium-dependent binding to 
mannose is described. The protein was isolated from alligator serum using mannose affinity 
chromatography and the N-terminal sequence was determined using Edman degradation. 
Enzymatic digestion with trypsin, α-chymotrypsin, Lys-C, Glu-C, and Asp-N proteases was used 
to generate peptide fragments for analysis by liquid chromatography tandem mass spectrometry 
(LC-MS/MS). Separate analysis of the protein digests with multiple enzymes extended the 
protein sequence coverage. De novo sequencing was accomplished using Mascot Distiller and 
PEAKS software and the sequences were searched against the NCBI database using Mascot and 
BLAST to identify homologous peptides. A 35 kDa protein was identified as an alligator lectin. 
6.1 Introduction 
Animal lectins comprise three major families: S-type lectins, P-type lectins, and C-type 
lectins.297 S-type lectins (also known as galectins) are found in the cytoplasm and nucleus of 
cells and sometimes on cell surfaces.298 This family of lectins is involved in cell adhesion and 
plays an important role in normal development of multicellular animals.298 P-type lectins target 
lysosomal enzymes in their subcellular compartment,299 and they differ from other lectins in that 
they have the ability to recognize phosphorylated mannose residues. The C-type lectins bind to 
carbohydrates in a calcium-dependent manner and are grouped into three classes: endocytic 
lectins, collectins, and selectins.298  
 *The work reported in the chapter has been submitted to Comparative Biochemistry and 
Physiology – Part B: Biochemistry & Molecular Biology. The protein sequence data reported in 
this paper will appear in the UniProt Knowledgebase under the accession number P86928. 
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Endocytic lectins are found in cell membranes and are specific for different sugars, for example 
mannose, which is found on the cell surface of microorganisms.298 Endocytic lectins act as 
opsonins, binding to the cell surface carbohydrates on microorganisms, stimulating phagocytisis 
by leukocytes, and eventually death. Collectins function in a similar way to endocytic lectins; 
they bind to microorganisms that have mannose glycans on their surfaces, leading to lysis of the 
pathogen and activation of the innate immune system.297 Selectins direct the movement of 
leukocytes to sites of inflammation.300 The importance of animal lectins is increasingly 
recognized and studied because of their critical roles in host defense and potential for novel 
medical applications.301 
Among the family of animal lectins, the C-type lectin known as mannose-binding lectin 
(MBL) has been well characterized in humans and some other animals.302, 303 Mannose-binding 
lectin is a calcium-dependent protein found in the serum of mammals.304 This protein, which is 
generated in the liver, tags the surface of bacteria making them susceptible to destruction.304 The 
C-type lectin consists of a collagen-like domain which interacts with cells that have been 
targeted by the innate immune system.305 Binding of MBL to target cells activates the serum 
complement component of the immune system, which is an important element of innate 
immunity305 and consists of a set of plasma proteins that attack extracellular pathogens.306 
Complement proteins play an important role in innate immunity. The innate immune system can 
identify foreign material by recognizing pattern receptors, such as mannose, that are found on the 
surface of pathogens.306, 307  
Another family of animal lectins that bind to carbohydrates in a calcium-dependent 
manner is intelectins.307 Intelectins exhibit high sequence homology and have been identified in 
many organisms including human,308 mice,309 frogs,310 trout,311 and ascidians.312 The principal 
function of intelectins is to participate in cell differentiation,313 apoptosis,314 and recognize tumor 
100 
 
antigens.315 However, they also recognize pathogens and bacterial components and have roles in 
innate immunity.307 Hence, they behave similarly to C-type lectins. 
Reptilian lectins such as those from lizards316 and snakes317 have been isolated and 
characterized. However, limited information is available for alligator lectins. Alligators have a 
potent immune system and their serum produces a broader antibacterial activity compared to 
other vertebrates such as humans.318 Hence, characterization of lectins from alligator serum may 
provide a better understanding of the structure-function relationship of their immune system. 
Lectins from different species such as Turbo (Lunella) coreensis,319 Bubalus bubalis,320 
Halocynthia roretzi,312 and Salmo salar321 have been isolated and identified using Edman 
degradation and cDNA cloning.322-324 However, mass spectrometry is a more commonly used 
tool for protein sequencing and identification.325 Tandem mass spectrometry (MS/MS) in 
conjunction with separation techniques is a commonly used approach to sequence and 
characterize proteins derived from complex mixtures.325 A recent study showed the use of mass 
spectrometry to characterize the primary sequence of a galactose-binding lectin from the seeds of 
a legume plant.326 In addition to this study, several other studies have been conducted that 
demonstrate the utility of mass spectrometry for identifying lectin sequences.327-329  
One of the major challenges in the study of alligator proteins is the limited information 
available on the reptilian genome and proteome. For proteomic analysis of species with limited 
proteomic data, de novo sequencing can be used to determine protein sequences.330 In typical de 
novo sequencing methods, proteins are isolated and enzymatically digested, and the resulting 
peptides are analyzed by tandem mass spectrometry. The sequence is determined by observing 
the mass differences between fragment peaks in the tandem mass spectra that are generated by 
fragmentation of the peptide of interest.331 De novo sequencing was previously used to sequence 
peptides from proteins of the American alligator leukocytes.332  
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In the present study, mannose affinity separation was used to isolate a 35 kDa lectin 
protein from the serum of the American alligator (Alligator mississippiensis). Liquid 
chromatography ESI-MS and MALDI-MS was used to obtain the mass of the intact protein. The 
protein was digested using several different proteases. Peptide sequences were determined using 
de novo sequencing. Database searching and BLAST search was also used to match peptides 
with more than 50% homology. Using mass spectrometry and different enzymes independently, 
peptides of different lengths were generated and aligned to determine the sequence of the 
American alligator lectin. 
6.2 Experimental  
Proteins were isolated from alligator serum with affinity chromatography. Mannan 
agarose (3 mL) was equilibrated with 3 mL of mixing buffer (10 mM Tris-HCl, pH 7.8, 1.25 M 
NaCl) and allowed to settle into a column prepared from a Pasteur pipette plugged with cotton. 
Fresh alligator serum (5 mL) was mixed with 5 mL of loading buffer (20 mM Tris-HCl, pH 7.8, 
2.5 M NaCl). The diluted serum was allowed to filter through the column and the column was 
washed with 10 volumes of loading buffer. The proteins were eluted with 5 mL of elution buffer 
(10 mM Tris-HCl, pH 7.8, 1.25 M NaCl, 2 mM EDTA). The isolated lectin protein was 
transferred to 10 kDa centrifugal concentrator tubes and centrifuged at 7500 g to concentrate and 
desalt the sample. A portion of the concentrate was used for mass analysis before enzymatic 
digestion. 
The collected lectin samples were analyzed by reverse phase liquid chromatography (RP-
LC) ESI time-of-flight mass spectrometry (Agilent 6210) and matrix-assisted laser desorption 
ionization time-of-flight/time-of-flight tandem mass spectrometer to obtain the mass of the intact 
protein. For LC/MS, 10 µg of sample obtained from affinity separation was dissolved in 10 µl of 
water containing 0.1% formic acid (FA) and loaded onto a C18 reverse phase column 5 µm 250 × 
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mm (Vydac) which had been equilibrated with 0.1% FA in water. A linear gradient from 0% to 
60% of B over 60 minutes was used for protein separation. Solvent A was water containing 0.1% 
FA and solvent B was acetonitrile containing 0.1% FA. The eluent from the LC column was 
directed towards the mass spectrometer and mass spectra were acquired from 600 to 3000 m/z 
using ESI at 4200 V. The spectra were extracted and deconvoluted using Analyst software. 
The protein samples for MALDI analysis were deposited on a ground-steel target using a 
1:1 ratio (v/v) of sample and saturated matrix solution. The matrices used were a 9:1 mixture of 
2,5-dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid (sDHB) and 2,4-dimethoxy-3-
hydroxycinnamic acid (sinapinic acid, SA). The samples were analyzed in positive ion mode and 
500 shots were collected. The mass spectra were collected using a mass range from 20 to 90 
kDa. Exact masses from the spectra were determined using Bruker FlexAnalysis software.  
One-dimensional SDS-PAGE was performed using pre-cast 4–20% polyacrylamide 
gradient tris-HCl gels on the small format gel electrophoresis system. The samples were mixed 
1:1 v/v with sample buffer containing 62.5 mM tris-HCl at pH 6.8, 2% SDS, 25% glycerol (w/v), 
0.01% w/v bromophenol blue, and, in both the presence and absence of 10% 2-mercaproethanol 
(v/v), heated at 95ºC in a water bath for 5 minutes before loading on the gel. Samples were run at 
100 V for 1 h using tris-glycine (pH 8.3) as the gel running buffer. Gels were stained with 
Coomassie blue for 1 h and rinsed twice with distilled water for 10 min (each time) to remove 
the stain. The gel images were captured using the Gel Doc XR System and with BioRad Quantity 
One 1-D analysis software. Samples were excised from the SDS polyacrylamide gel and 
submitted for N-terminal sequencing by Edman degradation using a protein sequencer (Model 
494, Perkin Elmer Applied Biosystems).  
A purified alligator lectin (40 µg) was incubated in the presence of 40 µL of mannan-, 
mannose-, D-lactose-, N-acetylgalactosmine-, N-acetylglucosamine-, and β-D-glucose-agarose. 
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After 30-minute incubation at ambient temperature, the samples were centrifuged and a 20 µL 
aliquot of the supernatant (containing the unbound protein) was subjected to SDS-PAGE.  One-
dimensional SDS-PAGE was performed and the gels were stained with Coomassie blue. The 
experiment was repeated three times. The density of the bands, in pixels, was evaluated and 
compared using ImageJ software.333  
To obtain maximum sequence coverage, separate aliquots of lectin protein obtained from 
affinity separation were subjected to several different enzymatic digestions. The protein fractions 
were dissolved in a 100 mM ammonium bicarbonate buffer adjusted to the pH range in which 
each endoprotease was most active. The protein was reduced using 50 mM DTT in 25 mM 
ammonium bicarbonate buffer and incubated at 37ºC for one hour. Following reduction, the 
protein was alkylated with 50 mM iodacetamide in 25 mM ammonium bicarbonate buffer for 45 
minutes at room temperature in the dark. The in-solution digestions were performed separately 
using trypsin, α-chymotrypsin, Lys-C, Glu-C, or Asp-N according to the manufacturer’s 
protocol. Briefly, digestion with trypsin was performed using a 1:20 ratio of enzyme to substrate 
in 100 mM ammonium bicarbonate, pH 8.5; with α-chymotrypsin using a 1:20 ratio at pH 8.5; 
with Lys-C using a 1:20 ratio at pH 8.5; with Glu-C using a 1:20 ratio at pH 7.8; and with Asp-N 
using a 1:50 ratio at pH 8.5. All digestions were run at 37ºC overnight. The enzymatic digests 
were dried in a vacuum centrifuge and resuspended in 0.1% FA for LC separation. 
Bands from the one-dimensional gels were excised and cut into ~1 mm cubes, and the 
stain was removed with 200 mM NH4HCO3 and 40% acetonitrile (2×30 min). After destaining, 
the gel pieces were dried in a vacuum centrifuge, rehydrated with 20 μL of 0.4 μg trypsin in 40 
mM ammonium bicarbonate containing 9% acetonitrile to completely cover the gel pieces. The 
tubes were then incubated overnight at 37°C.334 A similar approach was used for digesting the 
protein gel pieces using α-chymotrypsin, Lys-C, Glu-C, and Asp-N proteases.335, 336 Peptides 
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were extracted from gel pieces with 60% acetonitrile and 40% water containing 0.1% 
trifluoroacetic acid (TFA). CNBr digestions were performed overnight with 1 M CNBr at room 
temperature in the dark. The following day the CNBr digestion was dried completely using a 
speed-vac and resuspended in water containing 0.1% FA for ESI analysis. FA digestions were 
performed overnight at 37ºC. 
Liquid chromatography electrospray tandem mass spectrometry (LC MS/MS) was used 
to analyze the peptides derived from the in-gel and in-solution digests. The peptides were 
dissolved in 20 µL of 0.1% FA and 10 µL of the digest was injected onto a 0.3 × 1 mm trapping 
column (PepMap) on a nano-LC system (Ultimate,) at a flow rate of 10 µL/min. The peptides 
were eluted onto a 75 µm × 15 cm C18 column (Biobasic) and separated using a gradient of 5 - 
40% B over 90 minutes with a flow rate of 200 nL/min. The peptides were analyzed via a 
quadrupole time-of-flight mass spectrometer (QSTAR) and ionized using a nano-electrospray 
source at a voltage of 2.5 kV. The mass spectrometer was operated in information-dependent 
acquisition (IDA) mode. Three collision energies (25, 38, and 50 eV) were selected to fragment 
the peptides.  
The peptide sequences were generated from MS/MS data using Mascot Distiller and 
PEAKS software. The Mascot Distiller software determined amino acid sequences from MS/MS 
data using-peak fitting and isotope distribution241 and PEAKS software computes peptides for 
whose ions matches as many of the most abundant peaks in the spectrum.167 The de novo 
sequencing results were also verified manually. De novo peptide sequences were searched using 
Mascot and BLAST for protein identification based on homology searches. For Mascot and 
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peptides were produced from Asp-N digest. A less specific endoprotease, α-chymotrypsin, was 
also used to obtain additional overlapping peptides. The endoprotease α-chymotrypsin produced 
seven fragments that overlapped with fragments generated from trypsin, Asp-N, and Lys-C. 
There was no additional sequence coverage obtained from the CNBr and FA digest. 
Peptides obtained from the in-solution and in-gel digests of the 35 kDa band were de 
novo sequenced. Figure 4 shows mass spectra for a Glu-C and tryptic digest of the protein to 
illustrate peptide sequence determination. Figures 6-4a and 6-4b show examples of mass spectra 
acquired at 57 and 58 min, respectively, in the separation of the Glu-C and tryptic digests. 
Tandem MS data were collected and peptide sequences were determined via de novo sequencing. 
Figures 6-4c and 6-4d illustrate the peptide fragment series generated from the MS/MS data 
acquired from the ion 492.8 in Figure 4a and 743.8 in Figure 6-4 b. The sequences were searched 
against the NCBI protein database using Mascot and no protein matches were found. The de 
novo sequenced peptides were subjected to a BLAST search to identify proteins with similar 
sequences. Peptide sequences found with BLAST exhibited strong similarity to intelectin-1 and 
intelectin-2 proteins from mammals. Some of the lectin peptide sequences showed a high degree 
of similarity to the intelectin peptides, with few amino acid differences; these regions of 
similarity appear to be conserved among the lectins. The de novo sequenced peptides that did not 
match peptides in the protein database with a high degree of similarity appear to be regions of 
the alligator lectin sequence that are unique.  
The peptides from the different enzymatic digests produced overlapping data that were 
aligned to create the primary sequence of the protein (Figure 6-5). Partial protein sequences were 
generated when peptide sequences from the different digests were overlapped. Multiple 
alignments of the 35 kDa alligator lectin peptides with peptides of other lectin proteins provided 
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Figure 6-5. Primary structure of the 35 kDa lectin protein isolated from American alligator 
assembled from different endoprotease digestions. The peptide sequences were generated using 
ESI-MS/MS. Peptides obtained from the different enzymes was highlighted using different 
colors. 
 
6.3.3 Binding Activity of Alligator Lectin 
The alligator lectin-binding activity was determined for four carbohydrates, and the 
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6.3.4 Comparison of the 35 kDa Alligator Lectin Sequence with Other Animal Lectins  
The alligator lectin sequence was compared with other calcium-dependent animal lectins, 
specifically mannose-binding lectins and intelectins, from six other species: Homo sapiens, Mus 
musculus, Rattus norvegicus, Pan troglodytes, Gallus gallus, and Xenopus tropicalis using 
DIALIGN software. A sequence comparison for the lectin of the above organisms to the alligator 
lectin sequence resulted in 13%, 3%, 1%, 5%, and 4% sequence similarity, respectively.  
Sequence comparison of the alligator lectin sequence to intelectin-1 from Homo sapiens, 
Mus musculus, Rattus norvegicus, and Xenopus tropicalis, exhibited 57%, 59%, 60%, and 57% 
similarity respectively (Figure 6-7). A sequence comparison of the 35 kDa alligator lectin protein 
was also made with intelectin-2 from Homo sapiens (58% identity) and Mus musculus (59% 
identity). The degree of similarity of alligator lectin protein sequence to intelectin-2 sequence 
(Appendix B, Figure 1) is close to that of the intelectin-1. Both mannose-binding lectin and 
intelectin proteins bind in a calcium-dependent manner.307 However, sequence comparisons 
suggest that the lectin protein isolated here is more closely related to intelectins rather than to 
mannose-binding lectins. 
For the human intelectin-1, residue 154 is the start of the consensus sequence (Asn-X-
Thr/Ser) indicating a site of N-linked glycosylation. However, this site is not present in the 
alligator lectin sequence, indicating that it lacks N-glycosylation at this site. There are several 
possible sites of glycosylation in the alligator lectin sequence, for example at the serine and 
threonine residues, suggesting that O-linkage is possible. BLAST search of the alligator lectin 
sequence showed a conserved fibrinogen-related domain near the N-terminus region of the 
sequence between residues 50 to 80. The fibrinogen related domain has been shown to be similar 
to the calcium-dependent carbohydrate-recognition domains.338 Both mouse and human 
intelectin-1 sequences have a fibrinogen domain between residues 32 to 251 and 32-255 
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respectively. A comparison of the alligator lectin sequence to both mouse and human intelectin-1 




















Figure 6-7. The Alligator mississippiensis 35 kDa lectin amino acid sequence was compared to 
intelectin-1 protein of Homo sapiensis, Mus musculus, Rattus norvegicus, and Xenopus 
tropicalis. 
 
Previous reports show that many vertebrate lectins contain homologous amino acid 
sequences.303 The 35 kDa alligator lectin sequence shows a high degree of similarity to 
Mouse           MTQLGFLLFIMVATRG-----------------------CSAAEENLDTNRWGNSFFSSL 37 
Rat             MTQLGFLLFLIVATRG-----------------------GSAAKEDLETNKGTHSFFDSL 37 
Human           MNQLSFLLFLIATTRG-----------------------WSTDEANTYFKEWTCSSSPSL 37 
Frog            MLVYSLLVFALGFPAGHAGSCEQASISEKKEKILNLLACWTEDKTDNSGSRFSGSPTGDM 60 
Alligator       NNQLALKLAATGGSTNX----------------------LPALALQNLLNTWEDTSCCSQ 38 
                   .: :     . .                        .    :   .    :   .  
 
Mouse           P---RSCKEIKQEHTKAQDGLYFLRTKNGVIYQTFCDMTTAGGGWTLVASVHENNMRGKC 94 
Rat             S---RSCKEIKEENTGAQDGLYFLRTENGVIYQTFCDMTTAGGGWTLVASVHENNMGGKC 94 
Human           P---RSCKEIKDECPSAFDGLYFLRTENGVIYQTFCDMTSGGGGWTLVASVHENDMRGKC 94 
Frog            SYGYRSCNEIKSSDPSAPDGIYTLATEHGESYQTFCDMTTNGGGWTLVASVHENNMFGKC 120 
Alligator       T----SPGQQSWPRDGAQDGLYTLSTADGEIYQTFCDMSTHGGGWTLVASVHENNAHGKC 94 
                .    *  : .     * **:* * * .*  *******:: *************:  *** 
 
Mouse           TVGDRWSSQQGNRADYPEGDGNWANYNTFGSAEAATSDDYKNPGYFDIQAENLGIWHVPN 154 
Rat             TVGDRWSSQQGNRADYPEGDGNWANYNTFGSAEGATSDDYKNPGYFDIQAENLGIWHVPN 154 
Human           TVGDRWSSQQGSKAVYPEGDGNWANYNTFGSAEAATSDDYKNPGYYDIQAKDLGIWHVPN 154 
Frog            TVGDRWSTQQGNTLQNPEGDGNWANYATFGLPEGATSDDYKNPGYYDIQAKNLALWHVPN 180 
Alligator       TVGDRWSSQQGNSPLYPEGDGNWANNNIFGSAMGSTSDDYKNPGYYDLQAGDLSVWHVPD 154 
                *******:***.    *********   ** . .:**********:*:** :*.:****: 
 
Mouse           KSPLHN--WRKSSLLRYRTFTGFLQHLGHNLFGLYKKYPVKYGEGKCWTDNGPALPVVYD 212 
Rat             NSPLHS--WRNSSLLRYRTFTGFLQHLGHNLFGLYQKYPVKYGEGKCWTDNGPALPVVYD 212 
Human           KSPMQH--WRNSSLLRYRTDTGFLQTLGHNLFGIYQKYPVKYGEGKCWTDNGPVIPVVYD 212 
Frog            NTPMFN--WRNSSILRYRTQNSFFTEEGGNLFELYKKYPVKYDIGKCLADNGPAVPVVYD 238 
Alligator       RAPLRKEMIESSVLLFYR--TGFLSSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYD 212 
                .:*:     ..* :* **  ..*:   * **: :*:******. *.* .****.:*:*** 
 
Mouse           FGDARKTASYYSPSGQREFTAGYVQFRVFNNERAASALCAGVRVTGCNTEHHCIGGGGFF 272 
Rat             FGDAQKTASYYSPYGQKEFTAGFVQFRVYNNERAASALCAGMKVTGCNSEAHCIGGGGFF 272 
Human           FGDAQKTASYYSPYGQREFTAGFVQFRVFNNERAANALCAGMRVTGCNTEHHCIGGGGYF 272 
Frog            LGSAEKTSSLYSPNGRNEFTAGFVQFRVVNTEKAALALCPGVKVKGCNAEHHCIGGGGYF 298 
Alligator       FGSAEKTAAYYSPSGRGEFTAGFVQFRVFNNEKAPMALCSGLKVTGCNTEHHCIGGGGFF 272 
                :*.*.**:: *** *: *****:***** *.*:*. ***.*::*.***:* *******:* 
 
Mouse           PEGNPVQCGDFASFDWDGYGTHNGYSSSRKITEAAVLLFYR 313 
Rat             PEGNPLQCGDFGAFDWNGYGTHIGYSSSREITEAAVLLFYR 313 
Human           PEASPQQCGDFSGFDWSGYGTHVGYSSSREITEAAVLLFYR 313 
Frog            PEGSPRQCGDFSAFDWDGYGTHAGWSASKEITEAAVLLLYR 339 
Alligator       PEGNPRQCGDFPAFDWDGYGTHQSWSTSREMIESSVLLFYR 313 
                **..* ***** .***.***** .:*:*::: *::***:** 
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intelectins; however, intelectin proteins are animal lectins that typically have an affinity to 
galactose- and galactofuranose-binding C-type lectins and require calcium for carbohydrate-
binding activity.307 Although intelectins have been previously reported in other organisms, few 
studies have identified their binding specificity. In this study, the 35 kDa protein identified as 
alligator lectin had an affinity to mannose with a calcium-binding dependence. A previous report 
indicated that a rainbow trout intelectin had a binding specificity for both N-acetylglucosamine 
(GlcNAc) and mannose saccharides.311 The alligator lectin could be a similar intelectin-like 
protein that has a binding specificity for mannose residues.  
Intelectin proteins are oligomeric; for example, human intelectin-1 is a trimeric 
protein.339 ESI and MALDI analysis (Figures 6-2b and 6-3) suggests that the alligator lectin is an 
oligomeric protein that exists primarily as a 35 kDa monomer in vitro.  
Mammalian intelectins usually have at least 10 conserved cysteine residues339 for 
example as in human intelectin-1 (Figure 6-6); the 35 kDa alligator lectin sequence has nine 
cysteine residues. It has cysteine residues at positions 35 and 36 at the N-terminus region that are 
not present in the intelectin sequences of other vertebrates. Also, the alligator lectin sequence 
lacks a cysteine at position 42 that is conserved in the other organisms. These cysteine residues 
can influence tertiary protein structure, as well as carbohydrate-recognition specificity and 
oligomer formation and structure. When comparing the sequence to those derived from other 
vertebrates, the lack of a cysteine residue at position 41 in the alligator lectin sequence, as well 
as the different locations of the other cysteine residues may result in lower thermal stability of 
the protein.   
In addition to the presence of the cysteine residues that allow for oligomers to form via 
disulfide bonding, intelectins also have carbohydrate recognition domains.340 The calcium-
dependent carbohydrate-recognition domains are similar to the fibrinogen-like domain. 
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Fibrinogen-like proteins typically contain fibrinogen domains at the C-terminal region in both 
vertebrates and invertebrates.338, 341 An example of a human fibrinogen-like protein is ficolin. 
Although ficolin does not show sequence homology to C-type lectins or intelectins, it plays a 
vital role in innate immunity in a manner similar to the mannose-binding lectin.342 There are two 
types of ficolins found in humans, ficolin-α which is a 326 amino acid protein and has a 
fibrinogen terminal domain at residues 109 to 326, and ficolin-β, a 313 amino acid protein with a 
fibrinogen terminal domain at residues 96 to 313.338 The alligator lectin sequence has low 
sequence similarity to both the fibrinogen domains in human ficolin-α (16% similarity) and 
ficolin-β (9% similarity) (Appendix B, Figure 2), suggesting that its carbohydrate-recognition 
domain is different to that found in ficolin proteins. BLAST results for the alligator lectin 
showed that it has a fibrinogen-related domain between residues 50 and 80, suggesting that its 
carbohydrate recognition domain is near the N-terminal region of its sequence as previously 
shown in the Halocynthia roretzi lectin from ascidian plasma.312 
Binding studies were conducted with several carbohydrates leading to the conclusion that 
the alligator lectin exhibits strong selectivity for both mannan and mannose, which functions as a 
recognition molecule in the complement system. The alligator lectin showed some binding 
activity towards D-lactose suggesting that the lectin may also bind to terminal galactose as 
observed with intelectins from other organisms. The weak binding of the lectin observed in the 
presence of β-D-glucose, N-acetylglucosamine, and N-acetylgalactosamine, suggests that the 
lectin has limited binding specificities for these carbohydrates.  
6.4 Summary 
Sequence data collected from a 35 kDa protein isolated from the serum of Alligator 
mississippiensis, using a mannose affinity column, indicated that it is a lectin protein comprising 
approximately 313 amino acids. Mass spectrometry analysis of different enzymatic digests, from 
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both in-gel and in-solution, was used to generate peptide sequences by MS/MS and de novo 
sequencing as well as database searching with Mascot and BLAST. Using sequence alignment 
tools, peptides from the lectin protein were aligned with lectin proteins from other vertebrates 
and peptides from the different digests were overlapped to assemble the protein sequence.  
The primary structure of the alligator lectin exhibited more than 50% similarity to human, 
mouse, rat and frog intelectin-1 protein and less than 15% homology to mannose-binding lectin 
from other vertebrates. Although the alligator lectin showed a higher degree of similarity to 
intelectin protein, the differences of the conserved cysteine residues between the alligator and 
other vertebrate intelectins may result in structural differences. Strong homology to the 
fibrinogen-like domain of the alligator lectin was observed near the N-terminus region. There 
were no putative N-glycosylation sites identified in the alligator lectin sequence; however it has 
potential O-linkages. The isolated alligator lectin exhibited strong binding affinities toward 
mannose and mannan as compared to other tested carbohydrates. 




CHAPTER 7. A MASS SPECTROMETRY APPROACH FOR THE STUDY OF 
DEGLYCOSYLATED PROTEINS* 
 
The work described in this chapter focuses on preparatory steps to remove salts and 
buffers for mass spectrometry (MS) analysis after enzymatic or chemical deglycosylation. In this 
work, the glycosylated protein fetuin and a lectin protein isolated from the serum of Alligator 
mississippiensis were used to evaluate methods for desalting samples after an enzymatic or 
chemical deglycosylation. Precipitation and dialysis were used to prepare the deglycosylated 
samples for MS analysis. Both the precipitation and dialysis methods were suitable for sample 
preparation prior to analysis by matrix assisted laser desorption ionization (MALDI) MS.  
7.1 Introduction 
Proteomics is the study of the structure and functions of proteins in an organism or tissue, 
and mass spectrometry is now a routinely used method for protein identification in complex 
mixtures.125 Prior to a typical mass spectrometry analysis, separation techniques such as two-
dimensional gel electrophoresis and high performance liquid chromatography (HPLC) are used 
to reduce the complexity of protein mixtures.125, 325  
 Some proteins are post-translationally modified to help regulate gene expression, protein 
turnover, and cellular structure.343 Glycosylation is a common post-translational modification 
that is involved in biological functions such as immune recognition and inflammation.344 There 
are two major types of protein carbohydrate linkages:  N- and O-linked glycosylation. With N-
glycosylation, the glycan is attached to an asparginine residue followed by any amino acid other 
than proline, which is linked to a serine or threonine residue. During O-glycosylation, the glycan 
is attached to a serine or threonine residue. Glycoproteins have been characterized by mass 
spectrometry, but this is challenging due to the heterogeneity of the carbohydrate moieties and  
*Reprinted by permission of the Elsevier. The work reported in this chapter has been 
published in the Microchemical Journal.4 
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the complexity of the resulting mass spectra.345 Glycosylation of the protein may also limit the 
extent of proteolytic digestion. To avoid this, the N- and/or O-linked carbohydrates can be 
removed prior to analysis.346, 347  
 Enzymatic or chemical removal of the glycan can be used for analysis of the protein 
without the attached oligosaccharides. An enzymatic approach using peptide: N-glycosidase 
(PNGase F)204 and a chemical approach using trifluoromethanesulfonic acid (TFMS)  have been 
used to remove the oligosaccharides.205, 348 PNGase F is an enzyme that removes N-linked 
oligosaccharides, leaving both the protein and oligosaccharides intact for further analysis. There 
is no enzyme that cleaves O-linked oligosaccharides. TFMS is a non-specific deglycosylating 
agent that cleaves both N-linked and O-linked oligosaccharides to leave the intact protein.349 
 The proteins used in this study were enzymatically or chemically deglycosylated 
followed by matrix assisted laser desorption ionization (MALDI) MS. The steps for both 
chemical and enzymatic deglycosylation have been reported previously,205, 350, 351 but the 
deglycosylated product requires cleanup prior to MALDI mass spectrometry. We have developed 
important sample desalting procedures that follow deglycosylation prior to mass spectrometry 
analysis, which are not clearly outlined in many procedures. This study focuses on the treatment 
of deglycosylated proteins for mass spectrometry analysis.   
7.2 Experimental 
7.2.1 Materials 
Fetuin, a plasma glycoprotein produced by the liver, was obtained from Sigma-Aldrich 
and the lectin protein was isolated from the blood plasma of Alligator mississippiensis. Blood 
from seven American alligators was collected, heparin added for anticoagulation, and the blood 
allowed to clot overnight at ambient temperature. The serum was collected and the lectin was 
isolated using mannan-agarose affinity chromatography.  
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7.2.2 Enzymatic Deglycosylation  
Proteins containing oligosaccharides attached through N-linked glycosylation were 
deglycosylated as described in Section 2.9. Approximately 100 µg of protein was dissolved in 18 
µl of nanopure water. Denaturing buffer (2 µl), containing 0.6 mg/mL SDS and 0.5 mg/mL DTT, 
was added and heated at 100ºC for 10 minutes to increase the rate of deglycosylation. The 
sample was incubated on ice at 0ºC for five minutes and centrifuged for 10 sec. To the denatured 
sample, a non-ionic detergent (NP-40) was added to prevent loss of enzyme activity. The 
PNGaseF enzyme was added to the sample and it was incubated at 37ºC for four hours.204, 352 
The intact protein was isolated from the mixture via protein precipitation, which removed the 
buffers that can interfere with the MALDI signal. Acetone or trichloroacetic acid (TCA) was 
used to precipitate the protein.353  
7.2.3 TCA Precipitation 
TCA precipitation was accomplished by the addition of one volume of 60% TCA. The 
sample was gently vortexed and incubated on ice overnight. The sample mixture was centrifuged 
at 10,000 g for 30 min and the supernatant was removed. Chilled acetone was added to wash the 
precipitate and it was centrifuged again at 10,000 g.80 This procedure was repeated twice. The 
precipitate was air-dried and suspended in aqueous 0.1% trifluoroacetic acid (TFA) or 0.1% 
formic acid (FA) for MALDI analysis. 
7.2.4 Acetone Precipitation 
Acetone precipitation was achieved by the addition of four volumes of acetone to the 
protein sample, followed by an overnight incubation on ice. The sample was centrifuged at 
10,000 g for 30 min at 4ºC. The supernatant was removed and the precipitate was air dried for 30 




7.2.5 Chemical Deglycosylation 
In-solution deglycosylation was performed using a deglycosylation kit (Prozyme) 
containing trifluoromethanesulphonic acid (TFMS). TFMS removes most glycan types from 
glycoproteins and leaves the protein intact.205 Briefly, approximately 0.3 mg of protein in a vial 
was dried overnight using a lyophilizer. The dried protein was capped with a septum and placed 
on a dry ice-ethanol bath for 20 seconds to reduce the temperature of the reaction. A mixture of 
TFMS and toluene solution was prepared and 50 µl was slowly added using a gas-tight syringe. 
Precautions were taken to prevent the dried protein from being exposed to moisture due to the 
potential for hydrolysis of the peptide bonds.205, 354 The vials containing the protein with TFMS 
mixture were incubated at -20ºC for five minutes then shaken briefly to help dissolve the protein. 
The solvation process was repeated and followed by a four-hour incubation at -20ºC.  
7.2.6 Dialysis 
Dialysis was performed prior to mass spectrometry analysis. After the four-hour 
incubation, the vials containing the samples were placed in a dry ice-ethanol bath for 20 seconds, 
and then 150 µl of pyridine solution was added to each vial. The vials were incubated on dry ice 
for five minutes, and then in a dry ice-ethanol bath for 15 minutes. A 400 µl quantity of 0.5% 
ammonium bicarbonate was added to each vial to neutralize the sample. Following 
deglycosylation, the protein was isolated using dialysis. Each sample was added to a dialysis 
cassette (Thermo Scientific, Rockford, IL, USA) and dialyzed against 10 mM ammonium 
formate for two hours at room temperature. The buffer was changed and dialysis was continued 






7.2.7 Mass Spectrometry  
Glycoproteins and deglycosylated proteins were analyzed in linear MS mode with the 
Bruker UltrafleXtreme MALDI mass spectrometer. The glycoproteins and the deglycosylated 
proteins (after dialysis or precipitation) were mixed on a steel target using a 1:1 ratio of sample 
and saturated matrix solution. The matrices used were 2-hydroxy-5-methoxybenzoic acid 
(sDHB) and 2,4-dimethoxy-3-hydroxycinnamic acid (sinapininc acid, SA). The samples were 
analyzed in positive ion mode and 500 shot averages were collected using a mass range from 30 
to 100 kDa. Masses were determined using FlexAnalysis software.  
7.3 Results and Discussion 
Two methods were used for deglycosylation: PNGaseF and trifluoromethanesulfonic 
acid. The N- and O-linked glycoprotein protein, fetuin, was enzymatically deglycosylated to 
remove N-linked oligosaccharides and chemical deglycosylation was used to remove both N- 
and O-linked oligosaccharides. Fetuin is a glycoprotein with 359 amino acids containing N-
linked glycosylation sites at Asn 99, 156 and 176, and numerous O-linked glycosylation sites.355 
As seen in Figure 7-1a, a mass of 45.3 kDa was measured for fetuin before deglycosylation 
which is consistent with previous studies.356 The deglycosylated fetuin was analyzed with 
MALDI after deglycosylation with PNGaseF and no further cleanup. No signal was observed 
possibly due to buffers used during the deglycosylation. Using acetone and TCA precipitation 
independently, the protein was separated from the PNGaseF released oligosaccharides. The 
deglycosylated protein from the pellet of fetuin gave a 39.5 kDa in the mass spectrum and was 
compared with the glycosylated fetuin using MALDI and a mass shift of 5.8 kDa was observed 
in the mass spectrum (Figure 7-1b). Both acetone and TCA precipitation yielded sufficient 
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CHAPTER 8. CONCLUSIONS AND FUTURE DIRECTIONS 
 
 In this dissertation, mass spectrometry based proteomics was used to study the alligator 
blood proteome. Proteins and peptides found in the leukocyte extracts from the alligators were 
identified using gel electrophoresis techniques, liquid chromatography, and mass spectrometry 
sequencing, including bottom-up and top-down sequencing. Several peptides and proteins with 
immunological functions, including lectin and antimicrobial peptides were isolated and 
identified. The significance of this work lies in that it provides insight on the function and 
evolution of both innate and adaptive immune systems of crocodilians.  
In Chapter 3, the proteome of the leukocytes was investigated because they are one of the 
most important cells in the body to participate at the site of an infection and play an important 
role in innate immunity. A 1- and 2-D gel electrophoresis system was used to separate leukocyte 
proteins, and enzymatic digest of the protein bands and spots using trypsin was applied to cleave 
the proteins to peptides for peptide sequencing. Using Mascot, a comparison was made between 
the experimentally observed fragment ions and the predicted fragments for all hypothetical 
peptides of a particular mass. From the MASOT search, 17 proteins were identified based on 
sequence homology. For MS/MS data that did not match any proteins in the database, peptide 
sequences were determined using de novo sequencing. Using the de novo sequencing results, 23 
proteins were identified based on peptide matching using BLAST. 
To further investigate peptides from the acidic leukocyte extracts that exhibited 
antimicrobial activity, a series of separations and antimicrobial tests were performed. Using 
reversed-phase chromatography, the leukocyte extracts (which consisted of a mixture of peptides 
and proteins) were separated, collected, and tested for antimicrobial activity. The initial eluents 
collected within the first 10 min exhibited activity and were further characterized using mass 
spectrometry and X-ray crystallography for identification, which was described in Chapter 4. 
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Small molecules less than 500 Da were identified, and the results indicated that the 
anticoagulant, EDTA, which was used during the blood collection, may have contributed to the 
antimicrobial activity. Due to the antimicrobial activity interferences from EDTA used in the 
work in Chapter 4, heparin was used as an alternative anticoagulant for the studies described in 
Chapter 5.  
To investigate the specific peptides and proteins from the alligator leukocytes that exhibit 
antimicrobial activity, peptides and proteins isolated from alligator leukocyte extracts were 
separated by reversed phase chromatography as described in Chapter 5. The antimicrobial 
activity of the peptides from the chromatographic fractions was tested for growth inhibition of 
various microbes to determine the antimicrobial spectrum of the peptides. Among the microbes 
studied, growth inhibition was observed for E. coli, E. cloacae and K. oxytoca indicating that the 
antimicrobial peptides from the alligator are active against gram-negative bacteria. Within a 
fraction that exhibited antimicrobial activity, two peptides at masses 4.7 and 4.9 kDa were 
identified using mass spectrometry. Due to the close mass of the peptides, ion mobility was used 
to determine whether the peptides can be separated based on their charge, size and shape. The 
separated peptide was analyzed using tandem mass spectrometry; however, limited sequence 
information was determined due to incomplete fragmentation. Therefore, the peptides were 
subjected to MALDI MS/MS for sequencing. Peptide sequences were determined using de novo 
and manual sequencing. From this work, the first antimicrobial peptides were isolated and 
partially characterized from Alligator mississippiensis and showed to have a net charge of +8 and 
+13 respectively at pH 5.5, indicating that they are cationic. Based on size and charge, these 
peptides exhibit strong characteristics similar to previously identified antimicrobial peptides. 
In Chapter 6, another class of immunological proteins, lectins, was studied which 
provides insight on the structure-function relationship of another class of proteins involved 
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within crocodile’s innate immune system.   A new calcium-dependent binding lectin protein was 
isolated from the serum of the Alligator mississippiensis by affinity chromatography using 
mannose columns. The sequence of this novel class of proteins from the blood serum of the 
alligator was determined with mass spectrometry and Edman sequencing and was used for 
homologous comparison with other lectins. Molecular masses of the isolated lectin were 
determined by ESI-MS and were found to be oligomeric which are consistent with the monomer, 
dimer, trimer and tetramer of the 35 kDa monomer lectin protein. The monomeric protein was 
enzymatically digested using four different proteases, creating small and large peptides, which 
were overlapped to enhance protein sequence coverage. The primary sequence of a novel lectin 
protein isolated from Alligator mississippiensis was determined, and its binding specificity to 
selected carbohydrates was studied.  
An approach to analyze proteins that have been glycosylated also was evaluated. In 
Chapter 7, preparatory steps used after deglycosylation procedures and before mass spectrometry 
analysis were described. Here, glycosylated proteins, fetuin and alligator lectin, were 
deglycosylated and methods for sample desalting and concentrating, such as precipitation and 
dialysis were used. The dialysis and precipitation methods were both suitable for sample 
preparation prior to MS analysis. A comparison between precipitation and dialysis procedures 
showed that precipitation methods produce higher protein signal, indicating a larger protein 
recovery. 
One of the future directions is to investigate other properties of the peptides, other than 
bacterial properties. Some antimicrobial peptides have shown to have anti-inflammatory, 
antifungal, antiviral and anti-tumor activity, so these properties should be investigated. Prior 
work showed that the crude leukocyte extract exhibited antimicrobial activity, so it is 
hypothesized that the activity may be due to multiple peptides. Therefore, the alligator leukocyte 
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extract should be further investigated for other antimicrobial peptides or proteins, other than the 
two peptides isolated in this work and their antimicrobial activity should be characterized, 
including the minimal inhibitory concentration (MIC) and the antimicrobial spectrum.  
The interaction of alligator antimicrobial peptides in the presence of microbes should also 
be investigated using a technique such as atomic force microscopy (AFM). This study can help 
provide an understanding of how alligator antimicrobial peptides affect bacterial cells. This 
effect may be based on the different models proposed as discussed in Section 1.1.1., for example, 
the carpet model, where peptides cover the membrane like a carpet and destroy the bacteria lipid 
bilayer.357 By reducing the AFM cantilever size to approximately 1000 times smaller than the 
normal size, the imaging speed can be increased without destroying the bacteria.358 The bacteria 
can be immobilized on poly-L-lysine coated cover slides (which will provide stronger cell 
adhesion) and imaged in aqueous solution to keep the cells alive. Alligator antimicrobial peptide 
can be added to the liquid droplet comprised of bacteria, at a concentration above the minimal 
inhibitory concentration (MIC) to acquire images.359 It is also necessary to evaluate the 
antimicrobial peptides presented in this dissertation for their suitability in commercial products, 
such as topical creams. They can be added to existing products to enhance the antimicrobial 
activity of the product and/or they can potentially be used as an antiseptic cream for cuts or an 
antifungal cream for infections such as athlete’s foot.      
The research in this dissertation also showed that lectin proteins are present and can be 
isolated from alligators. Therefore, additional studies should be performed to further characterize 
the identified lectin in this work, such as investigating the temperature and pH effect, and the 
effect of the identified alligator lectin on bacteria induced hemagglutination activity; which will 
indicate whether or not the lectin protects against bacterial induced erythrocyte damage. Because 
carbohydrates play a vital role in biological processes and diseases, lectins can be used to 
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identify certain diseases. Depending on the specificity of the alligator lectin it can potentially be 
used as a means to identify a particular disease state. Finally, antibodies against the alligator 
lectin discussed in this work can be prepared and used for isolation of lectins from other 
crocodilian species. This will provide more insight on lectins and their function within 
crocodilian species. 
Lastly, an exhaustive MS-based proteomics study should be performed to map all the 
proteins involved in the alligator’s immune system. The immune system is complex and made of 
several types of cells and proteins that play different roles in fighting infections. Therefore, a 
more comprehensive study of the structure-function relationship of the immune related proteins 
will help provide a better understanding of crocodilian immunity as well as provide more insight 
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APPENDIX A. PROTEINS MATCHED FROM DE NOVO SEQUENCING 
 
The peptide sequences in the table were generated from MS/MS data using de novo sequencing. De novo peptide sequences were 
subjected to database searching using BLAST to find proteins that contain sequences matching with the determined de novo 
sequences. The results were used to identify biological components that comprise the alligator leukocyte proteome (Chapter 3, Section 
3.3). 
 
Table A.1. Proteins identified at single peptide level using BLAST. De novo sequenced peptides obtained from gel digest were 
searched using BLAST and proteins were matched based on sequence similarity and evolutionary relationship using the SwissProt and 
MSDB database. The top three E-values are reported. 
 
 Band  
Number 
m/z Charge De novo Sequence Protein Accession Number Protein 
Length 
Organism E-Value 
          
 B4 1060.6 +2 EINLSPDSTSAVVSGLMVATK      
    EINLSPDSTSAVVSGLMVATK Fibronectin P11722.3 1256 Gallus gallus  2e-11  
(1st hit) 









Pleurodeles waltl  
 
9e-11 
 (2nd hit) 













 B4 536.3 +2 YEVSVYALK      
    YEVSVYALK Fibronectin P07589.4 2478 Bos taurus  0.33 
 (1st hit) 













 (2nd hit) 













 (3rd hit) 













 (4th  hit) 












 (5th hit) 
          
160 
 
YEVSVYALK Fibronectin  Q28275.2 522 Canis lupus familiaris  0.33 
 (6th  hit) 









Equus caballus  
 
0.33 
 (7th  hit) 









Homo sapiens  
 
0.33 
 (8th  hit) 









Xenopus laevis  
 
1.9 
 (9th hit ) 






































































 B4 701.3 +2 YQINQQWER      
    YQINQQWER Fibronectin P07589.4 2478 Bos taurus  0.013 
 (1st hit) 
    YQINQQWER Fibronectin P11276.3 2477 Mus musculus  0.013 
(2nd hit) 









Xenopus laevis  
 
0.013 
 (3rd hit) 





































Drosophila melanogaster  
 
27 
 (6th hit) 










Schizosaccharomyces pombe  
 
65 
(7th  hit) 
     
YQINQQ 
 



















Escherichia coli 536  
 
65 
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carbamoyltransferase (9th hit) 
     






















































 B1 613.9 +2 LIALLEVLSQK      
    LIALLEVLSQK Filamin-C NP_001449.3 2725 Homo sapiens  0.019 
 (1st hit) 













































































































 B1 487.3 +2 VYGPGVEPR      
    +YGPGVEP 50S ribosomal protein L25 
1 
YP_076110.1 205 Symbiobacterium thermophilum  15  
(1st hit) 
     
+YGPGVEP 
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VYGP VEP 
 










 B2 736.4 +2 AQQVSQGLDLLTAK      
    AQQVSQGLDLLTAK Vinculin P12003.4 1135 Gallus gallus  5e-05  
(1st hit) 























Sus scrofa  
7e-04  
(3rd hit) 














Mus musculus  
 
7e-04  
(4th  hit) 














Homo sapiens  
 
7e-04  
(5th  hit) 
     
QV+QGLD L AK 
 
Macrophage colony-












 B2 739.4 +2 MLGQMTDQVADLR        




P85972.1 1066 Rattus norvegicus  2e-05  
(1st hit) 







Sus scrofa  
 
2e-05  
(2nd  hit) 









Mus musculus  
 
2e-05  
(3rd  hit) 








































     














 B2 655.9 +2 TVTAMDVVYALK      
    TVTAMDVVYALK Histone H4 P83865.2 103 Litopenaeus vannamei  6e-04  
(1st hit) 









Olisthodiscus luteus  
 
6e-04  
(2nd  hit) 







Tetrahymena pyriformis  
 
6e-04  
(3rd  hit) 







Mytilus chilensis  
 
6e-04  
(4th  hit) 









Aplysia californica  
 
6e-04  
(5th  hit) 
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(6th  hit) 







Trichogramma cacoeciae  
 
6e-04  
(7th  hit) 







Diadromus pulchellus  
 
6e-04  
(8th  hit) 












(9th  hit) 







Pyrenomonas salina  
 
6e-04  
(10th  hit) 











(11th  hit) 







Triticum aestivum  
 
6e-04  
(12th  hit) 










(13th  hit) 







Volvox carteri  
 
6e-04  
(14th   hit) 





















































































































    TVTAMDVVYALK Histone H4 P40287.1 118 Entamoeba histolytica  6e-04  










































    TVTA+DVVYALK 
 
Histone H4 P62790.2 104 Sterkiella nova  0.011  
(29th hit) 




















































 B2 628.7 +2 LITKAVSASK      
    LITKAVSASK Histone H1.5 P43276.2 223 Mus musculus  0.49  
(1st hit) 




























































































     
LITKAV+ASK 
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    LI KAVSASK 
 
Histone H1 P84408.3 55 Salmo salar  9.3  
(20th hit) 
    LI KAVSASK Histone H1 P06350.2 207 Oncorhynchus  9.3 
(21st hit) 
 B6 833.9 +2 FSGSGSGTDFTFTISR      
    FSGSGSGTDFTFTIS Ig Κ chain V-I region Lay P01605.1 108 Homo sapiens  5e-06  
(1st hit) 
     
FSGSGSGTDFTFTIS 
 











     
FSGSGSGT+FTFTIS 
 










     
FSGSGSGTDFT TISR 
 







Homo sapiens  
 
2e-05 
 (4th hit) 
     
FSGSGSGTDFT TISR 
 










     
FSGSGSGTDFT TISR 
 











     
FSGSGSGTDFT TISR 
 











     
FSGSGSGTDFT TISR 
 











     
FSGSGSGTDFT TISR 
 







Homo sapiens  
 
2e-05 
 (9th hit) 
 B6 751.4 +2 VFGGGTKLTVLGQPK      
Table A.1. cont’d. 
166 
 
    VFGGGTKLTVL QPK Ig Λ chain V-III region 
LOI 
P80748.1 111 Homo sapiens  7e-05  
(1st hit) 
     
VFGGGT+LT+LGQPK 
 










     
VFGGGTKLTVLG 
 


























     
VFGGGTKLTVLG 
 











     
VFGGGTKLTVLG 
 











     
VFGGGTKLTVLG 
 










     
VFGGGTKLTVLG 
 











     
VFGGGTKLTVLG 
 










     
VFGGGTKLTVLG 
 











     
VFGGGTKLTVLG 
 











 B2 510.8 +2 V(I/L)ASFGEAVK      
    VLASFGEAVK Hemoglobin, β P02131.1 146 Caiman crocodilus  0.27 
(1st hit) 







































     
VL SFGEAVK 
 
























































































































          
    VL SFGEAVK Hemoglobin, β P07411.1 146 Vultur gryphus  2.1 
(14th hit) 
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 B2 500.8 +2 LSSPISGDPK      
    PISGDPK Microtubule-actin cross-
linking factor 1 
Q9UPN3.3 5430 Homo sapiens  54 
(1st hit) 










































     













     













     
LSSP  I+G+PK 
 










     













     













 B6 522.8 +2 IMSIVDPNR      
    IMSIVDPNR 
 
α-actinin-1 Q3B7N2.1 892 Bos taurus  0.1 
(1st hit) 
    IMSIVDPNR α-actinin-1 Q2PFV7.1 892 Macaca fascicularis  0.1 
(2nd hit) 



























    IMSIVDPNR α-actinin-1 P12814.2 892 Homo sapiens  0.1 
(5th hit) 
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 B5 506.2 +3 QEYDESGPSIVHR      




    QEYDESGPSIVHR Actin P53455.2 375 Ajellomyces capsulatus G186AR  3e-05 
(2nd hit) 
     
QEYDESGPSIVHR 
 
POTE ankyrin domain 
























































































































































     
QEYDESGPSIVHR 
 























          
Table A.1. cont’d. 
170 
 
QEYDESGPSIVHR Actin, cytoplasmic P12716.1 376 Pisaster ochraceus  3e-05 
(16th hit) 
 













     
QEYDESGPSIVHR 
 

















































     
QEYDESGPSIVHR 
 










     
QEYDESGPSIVHR 
 























     
QEYDESGPSIVHR 
 










     
QEYDESGPSIVHR 
 





































































































     
QEYDESGPSIVHR 
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 (35th hit) 


























     
QEYDESGPSIVHR 
 






























































     
QEYDESGPSIVHR 
 




































     
QEYDESGPSIVHR 
 










     
QEYDESGPSIVHR 
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QEYDESGPSIVHR 
 
























































































     
QEYDESGPSIVHR 
 























     
QEYDESGPSIVHR 
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QEYDESGPSIVHR 
 












































































































































     
QEYDESGPSIVHR 
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QEYDESGPSIVHR Actin, muscle Q00214.1 379 Styela plicata  3e-05 
(94th hit) 



























    QEYDE+GPSIVHR α-Actin-1 P53479.1 377 Cyprinus carpio  2e-04  
(97th hit) 














     
QEYDE+GPSIVHR 
 











 B1 683.9 +2 STDYGILQINSR      




    STDYGILQINSR Lysozyme C Q7LZI3.1 129 Tragopan satyra  6e-04  
(2nd hit) 
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STDYGILQINSR Lysozyme C P00705.1 147 Anas platyrhynchos  6e-04  
(11th hit) 
 
































































































































    STDYG+LQINSR 
 
Lysozyme C P00699.1 129 Callipepla californica  0.003 
(21st hit) 






























    STDYGIL+INSR Lysozyme C Q7LZQ2.1 129 Aix sponsa  0.004 
(24th hit) 
 B1 503.3 +2 WDAWDALK      
    WDAW+ALK Acyl-CoA-binding protein Q9PRL8.1 86 Gallus gallus  1.7  
(1st hit) 
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394 Homo sapiens  13 
(4th hit) 
    WDAW+ LK Acyl-CoA-binding protein P12026.2 87 Sus scrofa  18  
(5th hit) 







































 B4 509.8 +2 IGTMLPMQK      
    I TMLPM QK Peptidoglycan hydrolase 
flgJ 
Q9I4P4.1 400 Pseudomonas aeruginosa  15  
(1st hit) 
















     
IG MLPM K 
 
Arginine biosynthesis 











     
IG MLPM K 
 
Arginine biosynthesis 










     
G+MLPM+K 
 










 B1 565.3 +2 LVTDVQEAVR      
    LVTDVQEAVR Proactivator polypeptide 
(Containing Saposin-A, B, 
C & D) 
O13035.1 518 Gallus gallus  0.084  
(1st hit) 
























































































Burkholderia pseudomallei 1710b  
 
17 























































 B2 646.9 +2 ISMPDFDLNLK      
    ISMPDFDLNLK Neuroblast differentiation-
associated protein 
AHNAK 
Q09666.2 5890 Homo sapiens  0.001 
 (1st hit) 
     
ISMPDFD++ 
 












     
ISMPDFD++ 
 











     
ISMPDFD++ 
 











     
ISMPDFD++ 
 











     
ISMPDFD++ 
 











     
ISMPDFD++ 
 











     
ISMPDFD++ 
 











     
ISMPDFD++ 
 











     
ISMPDFD++ 
 











     
ISMPDFD 
 
DNA polymerase III 
subunit alpha 
Q9HXZ1.1 1173  




 B2 772.0 +2 AVASAAAALVLK      
    AVASAAAALVLK Talin-1 P26039.1 2541 Mus musculus  0.026  
(1st hit) 
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Chroomonas species  
 
6.8 
 (6th hit) 
 B2 525.8 +2 LGTFLENEK      
    LGTFLE+E Glutamyl-tRNA reductase Q2FTL0.1 424 Methanospirillum hungatei JF-1  36  
(1st hit) 














     









Schizosaccharomyces pombe  
 
87 
 (3rd hit) 

















 (4th hit) 




B0B7F9.1 354 Chlamydia trachomatis  117 
(5th hit) 
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 B4 821.9 +2 V(I/L)QQQADDAEER      
    V+QQQADDAEER Putative tropomyosin α-3 
chain-like protein 
A6NL28.2 223 Homo sapiens  0.006 
(1st hit) 
     
V+QQQADDAEER 
 










     
QQQADDAE+R 
 











    QQQADDAE+R  











     
QQQAD+AE+R 
 











     
QQQAD+AE+R 
 










 B6 587.3 +2 IPPKPPARAAR      
    PP+PPARAA Protein bassoon Q9UPA5.4 3926 Homo sapiens  17 
(1st hit) 









Xenopus laevis  
 
30 
 (2nd hit) 









































     
PPKPPA A 
 
























     
P  PPAR+AR 
 











 B5 506.8 +2 IPSLPSGVDK      
    PSLPSGVD Stromelysin-1 P08254.2 477 Homo sapiens  12  
(1st hit) 



























 B6 583.8 +2 AAGEIIAIPRR      
    AAGEIIAIPRR Envelope glycoprotein 
gp160 
Q89607.1 852 HIV-2 B_EHO  0.011  
(1st hit) 
     













          





A7GBW3.1 290 Clostridium botulinum F str. Langeland  22 
(3rd hit) 














 B1 831.4 +2 NSWGTSWGEDGYFR      
    NSWGTSWGEDGYFR Dipeptidyl-peptidase 1 
(Cathepsin C) 
Q60HG6.1 463 Macaca fascicularis  5e-07  
(1st hit) 




























 B5 684.9 +2 FRTTMLQDSIR      
    FRTTMLQDSI Origin recognition 
complex subunit 2 
Q75PQ8.1 576 Rattus norvegicus  0.014  
(1st hit) 






































Bos taurus  
 
0.20 
 (4th hit) 














 B6 586.8 +2 LPPEQGTTSSR      




XP_002686199.1 2920 Bos Taurus (flamingo homolog, Drosophila) 0.36 
(1st hit) 




































































 B6 593.3 +2 AILYNYWDK      
    AILYNYWDK Complement component 
c3 
CAC69535.1 401 Crocodylus niloticus  0.50 
(1st hit) 
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ILYNYWD 
 









































 (7th hit) 
 B6 506.8 +2 NEALIALLR      
    NEALIALLR Plastin-2 Q6P698.1 624 Danio rerio  0.79 
(1st hit) 
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Table A.2. Proteins identified at single peptide level using BLAST. De novo sequenced peptides obtained from gel digest were 
searched using BLAST with a limited taxonomy, containing birds (taxid:8782), crocodiles (taxid:8493), turtles (taxid:8459), tuataras 




m/z Charge De Novo Sequence  Protein  Accession Number Protein Length  Organism E-Value 
 B4 1060.6 +2 EINLSPDSTSAVVSGLMVATK         
    EINLSPDSTSAVVSGLMVATK 
 
 Fibronectin  P11722 1256  Gallus gallus  2e-13  
(1st hit) 
 
    NLSP+S SA  Endoribonuclease Dicer  Q25BN1 1921  Gallus gallus  2.2  
(2nd hit) 
 
    NL P  TS  VSGL 
 
 Protein sidekick-1 
 
 Q8AV58 2169  
 
Gallus gallus  4.0 
(3rd hit) 
 B4 536.3 +2 YEVSVYALK         
    YEVSVYALK  Fibronectin  P11722 1256  Gallus gallus  
 
0.003 
 (1st hit) 













 (2nd hit) 














 B4 701.3 +2 YQINQQWER         
    YQINQ  ER  Solute carrier family 41 
member 2 
 
 Q5ZHX6 573  Gallus gallus  2.1 
(1st hit) 




    INQQW  Serine α-fibrinogenase  Q8JH85 258  Macrovipera lebetina  2.8 
(3rd hit) 


























     
YQ + QQWE 
  
Structural maintenance of 










 B1 613.9 +2 LIALLEVLSQK         


















     
LI +LE +LSQK 
  




























 B1 487.3 +2 VYGPGVEPR         
    VYGP VE  116 kDa U5 small nuclear 
ribonucleoprotein 
component 
 Q5F3X4 972  Gallus gallus  6.7  
(1st hit) 
 

















 B2 736.4 +2 AQQVSQGLDLLTAK         
    AQQVSQGLDLLTAK 
 
 Vinculin  P12003 1135  Gallus gallus  5e-07  
(1st hit) 















    LDLLT K  Probable ATP-dependent 
RNA helicase DDX10 
 Q5ZJF6 875  Gallus gallus  9.8  
(3rd hit) 
 B2 739.4 +2 MLGQMTDQVADLR         




     
Q+TDQVA LR 
  










 (2nd hit) 













 B2 655.9 +2 TVTAMDVVYALK         


















     
TVT     +D VYALK 
  
Rho guanine nucleotide 











     
T+T +DVVY 
  











 B2 628.7 +2 LITKAVSASK         
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 B6 833.9 +2 FSGSGSGTDFTFTISR         
    FSG GSG +FT  Large fibroblast 
proteoglycan 
 
 Q90953 3562  Gallus gallus  1.7  
(1st hit) 




     












 B6 751.4 +2 VFGGGTKLTVLGQPK         
    TVLGQP  Transmembrane protein 
184C 




     
GT LTVL Q K 
  












     












 B2 510.8 +2 VLASFGEAVK         




    VLASFGEAVK  Hemoglobin subunit β  P02130 
 








147  Gallus gallus  0.015 
(3rd hit) 
     
VL+SFGEAVK 
  










     
VLASFGEAV 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
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VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










     
VL SFGEAVK 
  










 B2 500.8 +2 LSSPISGDPK         








     
LSSP  I G+PK 
  










     
LSSP  I G+PK 
  






Gallus gallus  
 
13 
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 (4th hit) 
     
LSSP  I+G+P 
  










     
LSSP  I+G+P 
  











 B6 522.8 +2 IMSIVDPNR         
    IMSIVDPNR  α-actinin-1  P05094 893  Gallus gallus  
 
0.001 
 (1st hit) 













 (2nd hit) 



























 B5 506.2 +3 QEYDESGPSIVHR         






























     
QEYDESGPSIVHR 
  










     
QEYDE+GPSIVHR 
  































































 B1 683.9 +2 STDYGILQINSR         
    STDYGILQINSR  Lysozyme C  P84492 130  Chelonia mydas  5e-06 
(1st hit) 
 
    STDYGILQINSR  Lysozyme C  Q7LZI3 129  Tragopan satyra  5e-06 
(2nd hit) 
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    STDYGILQINSR  Lysozyme C  P00701 147   
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 B1 503.3 +2 WDAWDALK         
    WDAW+ALK 
 
 Acyl-coenzyme A binding 
protein 
 
 Q9PRL8 86  Gallus gallus  0.017 
(1st hit) 
    WDAW AL 
 
 Acyl-CoA-binding domain-








    W+ WDA  β-crystallin B3 
 
 P55165 211  Gallus gallus  11 
(3rd hit) 


























 B4 509.8 +2 IGTMLPMQK         

































     
TM   LPMQ 
  










     
TM   LPMQ 
  










 B1 565.3 +2 LVTDVQEAVR         
    LVTDVQEAVR  Saposin-A  O13035 
 
 
518  Gallus gallus  8e-04 
(1st hit) 
 
    VTDV EA  Cadherin-4  P24503 913  Gallus gallus  13 
(2nd hit) 
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 B2 646.9 +2 ISMPDFDLNLK         




     
DFDL+L 
  
Zinc finger FYVE domain-











     













     
IS+PDF 
  










 B2 772.0 +2 AVASAAAALVLK         




     
VASAAAA 
  













    V +AA+ALVL  NADH-ubiquinone 
oxidoreductase chain 2 
 O21398 346  Struthio camelus  7.3 
 (3rd hit) 
 B2 525.8 +2 LGTFLENEK         
    LGTFL N  EK  α-type phospholipase A2 
inhibitor anMIP 
 
 A1XRN2 166  Atropoides nummifer  2.1 
(1st hit) 
    LGTFL N  α-phospholipase A2 
inhibitor clone 09 
 
 B1A4R4 166  Lachesis muta muta  6.7 
(2nd hit) 
    LGTFL N  α-phospholipase A2 
inhibitor 
 B1A4R0 166  Lachesis muta muta  6.7 
(3rd hit) 














     
LGTF  LEN 
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 B4 821.9 +2 VIQQQADDAEER         
    VIQ QQ+D+ EE  Tenascin  P10039 
 
1808  Gallus gallus  0.29 
(1st hit) 















     
QQ   DDAEER 
  










    
 
 












     
+Q +AD   DAEER 
  










 B6 587.3 +2 IPPKPPARAAR         
    +PPKPPA  G2/mitotic-specific cyclin-
B2 




     
PPKP P RAA 
  






































     
PP PPAR  AR 
  
Histone H3-like 























 B5 506.8 +2 IPSLPSGVDK         




     
LPS VDK 
  













 (2nd hit) 
     
LPSG+D 
  











     
IP+LP+G 
  











 B6 583.8 +2 AAGEIIAIPRR         
    AGEI+ IP  Jumonji 
domain-containing protein 
 Q5ZHV5 425  Gallus gallus  24 
(1st hit) 




    IAIPR  Lysine-specific 
demethylase 3A 
 Q5ZIX8 1325  Gallus gallus  24 
(2nd hit) 














     
IIAIP 
  












     
IIAIP 
  











     
IIAIP 
  











     
IIAIP 
  











     
IIAIP 
  











     
IIAIP 
  












     
IIAIP 
  











     
IIAIP 
  











     
IIAIP 
  











     
IIAIP 
  











     
IIAIP 
  







































     












     
AAG   IIAI 
  






Gallus gallus  
 
58 




     
 
AAG   IIAI 
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APPENDIX B. LECTIN SEQUENCE 
 
Protein sequencing with MS/MS and de novo sequencing yielded almost full coverage of an alligator 
lectin. The sequence was compared to lectins from other vertebrates using DIALIGN software to 
investigate sequence homology (Chapter 6, Section 6.4.4).   
Figure 1. Alligator mississippiensis lectin sequence aligned with Homo sapiens and Mus musculus 
intelectin-2.  
  Human           MLSMLRTMTRLCFLLFFSVATSGCSAAAASSLEMLSREFETCAFSFSSLPRSCKEIKERC 60 
Mouse           -------MTQLGFLLFIMIATRVCSAAEEN----LDTNRWGNSF-FSSLPRSCKEIKQED 48 
Alligator       -------NNQLALKLAATGGSTNXLPALALQN--LLNTWEDTSCCSQTSPGQQSWPRD-- 49 
                        .:* : *    .:    .*       *       :   .: * . .  ::   
 
Human           HSAGDGLYFLRTKNGVVYQTFCDMTSGGGGWTLVASVHENDMRGKCTVGDRWSSQQGNKA 120 
Mouse           TKAQDGLYFLRTENGVIYQTFCDMTTAGGGWTLVASVHENNLRGRCTVGDRWSSQQGNRA 108 
Alligator       -GAQDGLYTLSTADGEIYQTFCDMSTHGGGWTLVASVHENNAHGKCTVGDRWSSQQGNSP 108 
                  * **** * * :* :*******:: *************: :*:************* . 
 
Human           DYPEGDGNWANYNTFGSAEAATSDDYKNPGYYDIQAKDLGIWHVPNKSPM--QHWRNSAL 178 
Mouse           DYPEGDGNWANYNTFGSAEGATSDDYKNPGYFDIQAENLGIWHVPNNSPL--HTWRNSSL 166 
Alligator       LYPEGDGNWANNNIFGSAMGSTSDDYKNPGYYDLQAGDLSVWHVPDRAPLRKEMIESSVL 168 
                 ********** * **** .:**********:*:** :*.:****:.:*:  .  ..* * 
 
Human           LRYRTNTGFLQRLGHNLFGIYQKYPVKYRSGKCWNDNGPAIPVVYDFGDAKKTASYYSPY 238 
Mouse           LRYRTFTGFLQRLGHNLFGLYQKYPVKYGEGKCWTDNGPAFPVVYDFGDAQKTASYYSPS 226 
Alligator       LFYR--TGFLSSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYDFGSAEKTAAYYSPS 226 
                * **  ****.  * **: :*:******  *.*  *****.*:*****.*:***:****  
 
Human           GQREFVAGFVQFRVFNNERAANALCAGIKVTGCNTEHHCIGGGGFFPQGKPRQCGDFSAF 298 
Mouse           GRNEFTAGYVQFRVFNNERAASALCAGVRVTGCNTEHHCIGGGGFFPEFDPEECGDFAAF 286 
Alligator       GRGEFTAGFVQFRVFNNEKAPMALCSGLKVTGCNTEHHCIGGGGFFPEGNPRQCGDFPAF 286 
                *: **.**:*********:*. ***:*::******************: .*.:****.** 
 
Human           DWDGYGTHVKSSCSREITEAAVLLFYR 325 
Mouse           DANGYGTHIRYSNSREITEAAVLLFYR 313 
Alligator       DWDGYGTHQSWSTSREMIESSVLLFYR 313 




























Ficolin-1       -MELSGATMARGLAVLLVLFLHIKNLPAQAADT-CPEVKVVGLEGSDKLTILRGCPGLPG 58 
Alligator       NNQLALKLAATGGSTNSLPALALQNLLNTWEDTSCCSQTSPGQQSWPRDGAQDGLYTLST 60 
                  :*:    * * :.  :  * ::**     ** * . .  * :.  :     *   *.  
 
Ficolin-1       APGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRGEKGDAGQSQSCATGPRNC 118 
Alligator       ADG-----EIYQTFCDMSTHGGGWTLVASVHENNAHGKCTVGDRWSSQQG-NSPLYPEGD 114 
                * *      :     : .  *.  .  .   :.:   *   *:: .: *. ...  *..  
 
Ficolin-1       KDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDTDGGGWTVFQRRMDGSVDFYRDWAAYKQG 178 
Alligator       GNWANNNIFGSAMG----STSDDYKNPGYYDLQAGDLSVWH--VPDRAPLRKEMIESSVL 168 
                 :  :.. * *.      . .   .     * :.*. :*::  : . . : ::    .   
 
Ficolin-1       FGSQLGEFWLGNDNIHALTAQGSSELRVDLVDFEGNHQFAKYKSFKVADEAEKYKLVLG- 237 
Alligator       LFYRTGFLSSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYDFGSAEKTAAYYSPSGR 228 
                :  : * :   ..*:  *  : . :  ..  ..:..  ..   .*  *:::  *    *  
 
Ficolin-1       -AFVGGSAGNSLTGHNNNFFSTKDQDNDVSSSNCAEKFQGAWWYADCHASNLNGLYLMGP 296 
Alligator       GEFTAGFVQFRVFNNEKAPMALCSG-LKVTGCNTEHHCIGGGGFFPEGNPRQCGDFPAFD 287 
                  *..* .   : .:::  ::  .   .*:..*  .:  *.  :     ..  * :     
 
Ficolin-1       HESYANGINWSAAKGYKYSYKVSEMKVRPA 326 
Alligator       WDGYGTHQSWSTSREMIESSVLLFYR---- 313 




Ficolin-2       -MELDRAVGVLGAATLLLSFLGMAWALQAAD--TCPEVKMVGLEGSDKLTILRGCPGLPG 57 
Alligator       NNQLALKLAATGGSTNSLPALALQNLLNTWEDTSCCSQTSPGQQSWPRDGAQDGLYTLST 60 
                  :*   :.. *.:*  *. *.:   *:: :  :* . .  * :.  :     *   *.  
 
Ficolin-2       APGPKGE--AGTNGKRGERGPPGPPGKAGPPGPNGAPGEPQPCLTGPRTCKDLLDRGHFL 115 
Alligator       ADGEIYQTFCDMSTHGGGWTLVASVHENNAHG-KCTVGDRWSSQQGNSPLYPEGD-GNWA 118 
                * *   :  .. . : *     ..  : .. * : : *:  ..  *  .     * *::  
 
Ficolin-2       SG--WHTIYLPDCRPLTVLCDMDTDGGGWTVFQRRVDGSVDFYRDWATYKQGFGSRLGEF 173 
Alligator       NNNIFGSAMGSTSDDYKNPGYYDLQAGDLSVWH--VPDRAPLRKEMIESSVLLFYRTGFL 176 
                ..  : :   . .   .     * :.*. :*::  * . . : ::    .  :  * * : 
 
Ficolin-2       WLGNDNIHALTAQGTSELRVDLVDFEDNYQFAKYRSFKVADEAEKYNLVLG--AFVEGSA 231 
Alligator       SSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYDFGSAEKTAAYYSPSGRGEFTAG-F 235 
                   ..*:  *  : . :  ..  ..::.  ..   .*  *:::  *    *   *. *   
 
Ficolin-2       GDSLTFHNNQSFSTKDQDNDLNTGNCAVMFQGAWWYKNCHVSNLNGRYLRGTHGSFANGI 291 
Alligator       VQFRVFNNEKAPMALCSGLKVTGCNTEHHCIGGGGFFPEGNPRQCGDFPAFDWDGYGTHQ 295 
                 :  .*:*:::  :  .. .:.  *      *.  :     ..  * :     ..:..   
 
Ficolin-2       NWKSGKGYNYSYKVSEMKVRPA 313 
Alligator       SWSTSREMIESSVLLFYR---- 313 
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